Owner

Untitled

Verification

VULVA

VULVA — COMPLETE CONSOLIDATED TABLE (ZERO-OMISSION)

Category	Condition	Etiology / Cause	Clinical Features	Gross Appearance	Histopathology (Key Exam Lines)	Malignancy Risk / Notes
Inflammatory	Vulvitis	Inflammation of vulva (labia majora + minora)	Pain, pruritus, irritation	Erythema ± edema	Depends on cause	Common, usually benign
	Irritant contact dermatitis	Urine, soaps, detergents, antiseptics, deodorants, alcohol	Intense pruritus → itch–scratch cycle	Red, oozing (“weeping”), crusted papules/plaques	Spongiotic dermatitis,liquid collects between epidermal cells	Trauma from scratching worsens
	Allergic contact dermatitis	Allergy to perfumes, creams, fabric chemicals	Similar to irritant type	Similar appearance	Hypersensitivity reaction	Requires allergen avoidance
Infective	HPV infection	HPV (esp. 6, 11; 16 oncogenic)	Warts(condyloma acuminata) ± VIN	Papillary / flat lesions	Koilocytosis	Oncogenic risk with high-risk types
	HSV-1 / HSV-2	Viral	Painful vesicles → ulcers	Vesicles, erosions	Multinucleated giant cells (TZANK cells with cowdry inclusions bodies,+ in VZV too)	Recurrent
	Neisseria gonorrhoeae	Bacterial STI	Purulent discharge	Inflamed gland openings	Neutrophilic inflammation	Can involve Bartholin glands
	Treponema pallidum	Syphilis	Painless chancre	Ulcer	Plasma cells, obliterative endarteritis	Primary syphilis
	Candida species	Yeast (non-STI)	Pruritus, soreness	Erythema ± discharge	Pseudohyphae	Common
Complication	Bartholin duct obstruction	Inflammation/infection	Painful swelling	Cyst ± abscess	Cystic dilation	Surgical relevance
Non-neoplastic epithelial disorders	Lichen sclerosus	Autoimmune (T-cell mediated)	Pruritus, dyspareunia, introital narrowing	Smooth white plaques (leukoplakia)	Thin epidermis, loss of rete pegs, dense homogenized subepithelial fibrosis, band-like lymphocytes	1–5 % → HPV-negative vulvar SCC
	Lichen simplex chronicus	Chronic irritation / scratching	Persistent pruritus	Thickened white plaques	Acanthosis, hyperkeratosis, ↑ basal mitoses, no atypia,Thickened epidermis	Not premalignant; reactive
Benign tumor-like lesions	Condylomata lata	Secondary syphilis	Moist lesions	Flat plaques	Plasma cell infiltrate	Infectious marker
	Condylomata acuminata	HPV 6 & 11 (>90 %)	Usually asymptomatic	Papillary or flat warts	Acanthosis + hyperkeratosis + koilocytosis	Not precancerous
Malignant	Vulvar carcinoma (overall)	Multifactorial	Ulcer, mass, pruritus	Leukoplakia → ulcer/exophytic	Invasive SCC	~3 % GYN cancers
	HPV-positive SCC pathway	HPV-16 ± smoking	Middle-aged	Warty, multifocal	Basaloid cells, poor differentiation, high N:C ratio, minimal keratinization	Slow progression
	HPV-negative SCC pathway	Lichen sclerosus → dVIN	Elderly	Unifocal, keratinizing	Well-differentiated, keratin pearls, prominent keratinization	More aggressive
Special malignancy	Extramammary Paget disease	Epidermal progenitor cells	Eczema-like pruritic plaque	Red, scaly, crusted	Large pale Paget cells, mucin-positive (PAS)	Usually no underlying carcinoma
Spread & prognosis	Vulvar SCC spread	—	—	—	Depth-dependent invasion	Inguinal nodes first
	Survival	—	—	—	—	70–93 % (node-negative) vs 25–41 % (node-positive)

Exam Lock 🔒 (One-Look Recall)

White thin vulva + fibrosis → Lichen sclerosus → HPV-negative SCC
Thickened epidermis + no atypia → Lichen simplex chronicus
Koilocytosis = HPV
Keratin pearls = HPV-negative vulvar SCC
Red scaly eczema-like vulva = Think Paget

NOTE-

🔹 Vulvitis

Vulvitis means inflammation of the vulva — the outer female genital area, including the labia majora (skin with hair) and labia minora (mucosa).

It’s common, usually painful and itchy, but not usually dangerous.

⚙️ Causes

Irritant or Allergic Contact Dermatitis

Irritant form → triggered by urine, soaps, detergents, antiseptics, deodorants, or alcohol.

It looks red and oozing (“weeping”) with crusting papules or plaques.

Allergic form → same look, but due to allergy to perfumes, additives in creams or lotions, fabric chemicals, etc.
Scratching (→ trauma) makes it worse and causes a “itch-scratch” cycle (pruritus → scratch → more inflammation).

Infections

Often sexually transmitted (STIs).

Common organisms:

Human papillomavirus (HPV) → condyloma acuminatum, vulvar intraepithelial neoplasia (VIN), and some squamous carcinomas.
Herpes simplex virus (HSV-1 / HSV-2) → genital herpes.
Neisseria gonorrhoeae → pus-forming infection of vulvovaginal glands.
Treponema pallidum → chancre of syphilis (primary lesion).
Candida species → yeast vulvitis (not sexually transmitted).

⚠️ Complication

Bartholin gland duct obstruction → painful cyst (Bartholin cyst) ± abscess formation.

🔹 Non-Neoplastic Epithelial Disorders

Lichen Sclerosus

Thinning of the epidermis + loss of rete pegs + dense homogenized fibrosis beneath the epithelium + band-like lymphocytic infiltrate.
Appears as smooth, white patches (“leukoplakia”) that may merge together.
Common in postmenopausal women and prepubertal girls.
Probably autoimmune (T-cell infiltrate + association with other autoimmune diseases).
Clinical effects: labial atrophy, narrowed vaginal opening → dyspareunia.
Malignancy risk: 1 – 5 % progress to HPV-negative squamous cell carcinoma of vulva.

Lichen Simplex Chronicus

Chronic irritation → thickened epidermis (acanthosis + hyperkeratosis) with increased mitoses in basal layers.
No cellular atypia.
Usually related to persistent pruritus or underlying dermatitis.
Produces white plaques (also called leukoplakia).
Cancer risk: not inherent — but often seen at edges of vulvar carcinomas → may reflect reactive change.

Figure 19-1 — Non-neoplastic vulvar epithelial disorders (A) Lichen sclerosus: thin epidermis + fibrosis + chronic inflammation. (B) Lichen simplex chronicus: thick epidermis + hyperkeratosis.

🔹 Tumors of the Vulva

Condylomas (Genital Warts)

Any warty vulvar lesion = condyloma.
Two types:

Condylomata lata – flat lesions of secondary syphilis.

Condylomata acuminata – HPV-related (> 90 % due to types 6 & 11 – “low-risk” HPV).\

Appearance → papillary or flat warty growths (red-pink to brown), often multiple, few mm to cm.
Histology: acanthosis + hyperkeratosis + koilocytosis (perinuclear vacuoles, wrinkled nuclei).
Not precancerous but signal HPV exposure → check for other HPV lesions in vagina/cervix.

Fig 19-2 A–B — Condyloma acuminatum: gross multiple warts & microscopic koilocytosis.

Carcinoma of the Vulva

~ 3 % of female genital tract cancers; mostly women > 60 yrs.
90 % = Squamous cell carcinoma.
Two distinct pathways:

HPV-related (16) — in middle-aged women ± smokers; precedes VIN (vulvar intraepithelial neoplasia).

Progression slow → years; not inevitable.

HPV-negative (lichen sclerosus related) — in elderly women with differentiated VIN (dVIN) precursor.

dVIN = atypia in basal layer + abnormal keratinization.

Histologic Feature	HPV-Positive SCC	HPV-Negative SCC
Degree of differentiation	Poorly differentiated	Well differentiated
Tumor cell type	Basaloid squamous cells	Mature squamous cells
Nuclear features	High nuclear-to-cytoplasm ratio, hyperchromatic nuclei	Relatively uniform nuclei
Keratinization	Minimal or absent	Prominent
Keratin pearls	Absent	Present
Intercellular bridges	Poorly formed or absent	Well formed
Growth pattern	Warty / papillary / exophytic	Solid nests and cords
Surface architecture	Papillomatous	Ulcerated or infiltrative
Mitoses	Numerous	Fewer
Koilocytosis	May be present	Absent
Stromal invasion	Present	Present

Morphology:

Lesions start as leukoplakia (± pigmented) → ulcerated or exophytic tumors.
HPV-positive type → multifocal, warty, poorly differentiated.

HPV-negative type → unifocal, well differentiated, keratinizing.

Spread → local invasion then inguinal lymph nodes; depth of invasion predicts risk.

Prognosis: 5-yr survival ≈ 70–93 % (no node spread) vs 25–41 % (with node metastasis).

Extramammary Paget Disease (Vulva)

Intra-epidermal proliferation of malignant epithelial cells (Paget cells).
Unlike Paget of breast → usually no underlying carcinoma.
Origin → epidermal progenitor cells.
Clinical: red, scaly, crusted plaque mimicking eczema or dermatitis.

Histology: large pale cells with finely granular cytoplasm + occasional vacuoles in epidermis; mucin positive on PAS stain.
May persist for years; if associated appendage carcinoma → invasive + metastatic potential.

Fig 19-3 — Paget disease of vulva: Paget cells in epidermis with chronic inflammation beneath.

VAGINA

🦠 Vaginitis

Common, transient inflammation → leukorrhea (vaginal discharge)
Predisposing factors: diabetes, antibiotic therapy, immunodeficiency, pregnancy, recent abortion
Causative organisms:

Candida albicans → curdy white discharge

• Normal flora in ≈ 5 % of women

• Symptomatic disease = needs predisposing factor / superinfection

Trichomonas vaginalis → sexually transmitted

• Watery, copious gray-green discharge

• Motile parasites on microscopy

• Found in ≈ 10 % of asymptomatic women

Primary Neisseria gonorrhoeae infection in vagina = rare in adults

⚠️ Malignant Neoplasms

1️⃣ Squamous Cell Carcinoma

Very rare
Usually > 60 y
Risk factors = similar to cervical carcinoma
Precursor: VAIN (vaginal intraepithelial neoplasia) — HPV-related
HPV DNA detectable in > 50 % cases

2️⃣ Clear Cell Adenocarcinoma

Seen in young women exposed in utero to DES (diethylstilbestrol)
Incidence < 1 / 1000 (but ≈ 40 × background)
Precursor = Vaginal adenosis (red granular mucosa with mucus-secreting/ciliated cells)

Microscopic (histologic) description

Tumor has cystic, papillary, tubular / glandular and solid architectural patterns with focal necrosis
Cells have distinct cell membranes, are large with moderate to abundant clear cytoplasm, occasionally may be oxyphilic
Cells are usually cuboidal and sometimes hobnail type with nuclei protruding into the lumen
Nuclei are round to irregular, hyperchromatic with conspicuous nucleoli

3️⃣ Sarcoma Botryoides (Embryonal Rhabdomyosarcoma)

Soft polypoid “grape-like” mass (protruding lesion)
Occurs in infants and children < 5 years (rare in young adults)

The tumor cells range from primitive small cells with hyperchromatic nuclei to stellate cells with delicate cytoplasmic processes to spindle cells with rhabdomyoblastic differentiation. The background stroma is loose myxomatous type. The tumor cells form a zone that is several layers thick (including the cambium layer described earlier).

The surface epithelium may show pseudoepitheliomatous hyperplasia mimicking carcinoma. There is strong immunoreactivity for myogenic antigens, including myogenin, muscle-specific actin, and desmin

VAGINA — INFLAMMATORY & MALIGNANT CONDITIONS (COMPLETE TABLE)

Category	Condition	Typical Age / Group	Etiology / Risk Factors	Discharge / Gross Features	Key Microscopy / Histology	Special Exam Notes
Inflammatory (Vaginitis)	General Vaginitis	Reproductive age	Diabetes, antibiotics, immunodeficiency, pregnancy, recent abortion	Leukorrhea (vaginal discharge)	Inflammatory changes	Common, transient
	Candida albicans	Any age	Normal flora (~5%) → symptomatic only with predisposing factor / superinfection	Curdy white discharge	Budding yeast, pseudohyphae	NOT STD
	Trichomonas vaginalis	Sexually active women	Sexually transmitted	Watery, copious gray-green discharge	Motile parasites on microscopy	~10% asymptomatic carriers
	Neisseria gonorrhoeae (primary vaginal infection)	Adults	STD	—	—	Rare in adults
Malignant Neoplasm	Squamous Cell Carcinoma	> 60 years	Same as cervical cancer (HPV, smoking, etc.)	Vaginal mass / ulcer	Invasive squamous carcinoma	Very rare
			Precursor: VAIN	—	—	HPV DNA detectable in >50%
Malignant Neoplasm	Clear Cell Adenocarcinoma	Young women	In-utero DES exposure	Vaginal mass	See below	Incidence <1/1000, 40× background
			Precursor: Vaginal adenosis	Red granular mucosa, mucus-secreting / ciliated cells	—	Classic USMLE / PGIM favorite
	Clear Cell Adenocarcinoma — Histology	—	—	—	Architectural patterns: cystic, papillary, tubular/glandular, solid + focal necrosis	Must list patterns
					Cells: large, cuboidal, clear cytoplasm (± oxyphilic)
					Hobnail cells (nuclei protruding into lumen)	🔑 buzzword
					Nuclei: round–irregular, hyperchromatic, prominent nucleoli
Malignant Neoplasm	Sarcoma Botryoides (Embryonal rhabdomyosarcoma)	Infants & children <5 y (rare in young adults)	Mesenchymal tumor	Soft, polypoid, grape-like protruding mass	Primitive small cells → stellate → spindle rhabdomyoblasts	Appearance is classic
					Loose myxomatous stroma
					Cambium layer (hypercellular subepithelial zone)	🔑 exam line
					Pseudoepitheliomatous hyperplasia of surface epithelium	Mimics carcinoma
					Immunoreactivity: myogenin, muscle-specific actin, desmin	Confirms myogenic origin

🔑 Ultra-High-Yield Exam Locks

DES → Clear cell adenocarcinoma → Vaginal adenosis
HPV → VAIN → Vaginal SCC
Grape-like vaginal mass in child → Sarcoma botryoides
Hobnail cells + clear cytoplasm = Clear cell adenocarcinoma
Candida needs a trigger; Trichomonas is an STD

CERVIX

CERVIX — Inflammation, Neoplasia & Benign Lesions (Complete Table)

Domain	Entity / Lesion	Key Points	Pathogenesis / Morphology	Natural History / Risk	Diagnosis / Screening	Management / Notes
Inflammatory	Cervicitis	• Very common • Presents with leukorrhea	• Infection of cervical epithelium	• Usually acute • Can persist if untreated	• NAAT for pathogen identification	• Empiric antibiotics active against Chlamydia + Gonococcus
	Infectious agents	• Chlamydia trachomatis (~40% STI clinic cases) • Ureaplasma urealyticum • Trichomonas vaginalis • Neisseria gonorrhoeae • HSV-2 • HPV	• Pathogen-specific epithelial infection	• HSV → risk of neonatal systemic infection if transmitted at birth	• NAAT	• Treat patient + partner(s)
Pre-neoplastic (Pathogenesis)	Cervical neoplasia – general	• Most tumors are epithelial • HPV-related	• Occurs at transformation zone (columnar → squamous metaplasia after puberty)	• Persistent high-risk 16,18HPV = key driver	• Cytology + HPV DNA testing	• Prevention via screening & HPV vaccination
	High-risk HPV	• HPV-16, HPV-18 ≫ others	• Infect immature squamous cells	• Persistent infection → SIL → carcinoma	• HPV DNA testing (≥30 y)	• Oncoproteins drive malignancy
	Oncoproteins	• E6 → inhibits p53 • E7 → inhibits RB	• Loss of cell-cycle control	• Genomic instability	• Indirect via cytology/HPV testing	• Central molecular mechanism
	Other risk factors	• Early first intercourse • Multiple sexual partners • Male partner with many partners • Persistent HPV	• ↑ HPV exposure + persistence	• ↑ lifetime cancer risk	—	• Epidemiologic risk clustering
Pre-invasive lesion	Squamous Intraepithelial Lesion (SIL)	• HPV-related pre-cancerous lesion	• Dysplasia of squamous epithelium	• Long latent period	• Pap smear	• Managed based on grade
	Age peaks	• SIL ~30 y • Invasive cancer ~45 y	—	• ~10–15 y progression window	—	• Key exam timeline
	LSIL (CIN I)	• Productive HPV infection	• Mild dysplasia • Preserved maturation	• 60% regress • 30% persist • 10% → HSIL	• Pap smear	• NOT premalignant • Observe
	HSIL (CIN II–III)	• True precancerous lesion	• ↑ proliferation • Loss of maturation	• 30% regress • 60% persist • 10% → carcinoma (~10 y)	• Pap + biopsy	• Excise / cone biopsy
Screening	Cervical screening	• Early detection of SIL	—	↓ cancer incidence	• Pap smear • Pap + HPV DNA ≥30 y	• Prevents invasive disease
Malignant	Invasive carcinoma – overall	• All are HPV-related	• Stromal invasion	• Metastatic risk depends on depth	• Biopsy + staging	• Treatment stage-dependent
	Histologic types (%)	• Squamous ~75% • Adeno / adenosquamous ~20% • Small-cell neuroendocrine <5%	• Squamous: keratinization common	• Neuroendocrine → aggressive	• Histopathology	• Cell type affects prognosis
	Adenocarcinoma trend	• Incidence rising	• Endocervical origin	• Often missed by Pap	• HPV DNA + biopsy	• Screening challenge
	Depth vs metastasis	• <3 mm invasion → <1% LN • >3 mm invasion → >10% LN	• Depth reflects stromal breach	• Key staging determinant	• Histologic measurement	• Exam-favorite statistic
	Morphology	• Tongues/nests of malignant squamous cells	• Desmoplastic stroma • ± keratin pearls	—	• Histology	• Classic appearance
	Clinical features	• Abnormal vaginal bleeding • Leukorrhea • Dyspareunia • Dysuria	• Local invasion	• Often late presentation	• Clinical + biopsy	• Red-flag symptoms
	Treatment	• Hysterectomy + LN dissection	—	—	—	• Microinvasive → cone biopsy • ± RT / CT
	Prognosis	• Depends on stage	• Neuroendocrine worst	—	—	• Stage is king
Benign	Endocervical polyp	• Common benign lesion	• Polypoid endocervical mucosa	• No malignant potential	• Speculum exam	• Reassurance / excision if symptomatic
	Gross features	• Smooth • Glistening • ± mucin-filled cysts	—	—	—	—
	Microscopy	• Epithelium: mucus-secreting columnar cells • Stroma: edematous + chronic inflammation • ± squamous metaplasia	—	—	• Histology	• May cause bleeding

Cervical Squamous Neoplasia — Complete Histological Continuum (One Table)

Feature	LSIL (CIN I)	HSIL (CIN II)	HSIL (CIN III / CIS)	Invasive Squamous Cell Carcinoma
Level of pathology	Intraepithelial	Intraepithelial	Intraepithelial (pre-invasive)	Stromal invasion present
Site	Transformation zone	Transformation zone	Transformation zone	Transformation zone
Depth of epithelial involvement	Lower ⅓ only	Lower ⅔ (to middle third)	Almost full thickness	Beyond basement membrane
Basement membrane	Intact	Intact	Intact	Breached
Epithelial maturation	Preserved	Partial loss	Almost complete loss	Lost (invasive growth)
Cellular differentiation	Mostly normal	Moderately abnormal	Markedly abnormal	Variable (poor → well differentiated)
Nuclear size & shape	Mild enlargement	Moderate pleomorphism	Severe pleomorphism	Marked pleomorphism
Chromatin pattern	Slightly irregular	Heterogeneous	Coarse, irregular	Coarse, hyperchromatic
Mitoses	Rare, basal only	↑ mitoses above basal layer (some atypical)	Numerous, abnormal at all levels	Numerous, atypical
Koilocytosis (HPV effect)	Prominent (superficial layers)	Occasional	Absent	Absent
Architectural order	Preserved layering	Partial disorganization	Severe disorganization	Tongues & nests invading stroma
Stromal response	None	None	None	Desmoplastic reaction
Keratin pearl formation	Absent	Absent	Absent	Present in well-differentiated tumors
Special variants	—	—	—	Rare neuroendocrine (small-cell–like)
Gross appearance	Not visible	Not visible	Not visible	Microscopic → exophytic / barrel cervix
Clinical palpation	Normal	Normal	Normal	Barrel cervix, fixed uterus
Parametrial involvement	No	No	No	Possible (uterine fixation)
Lymphovascular invasion	Absent	Absent	Absent	May be present
Risk of metastasis	None	None	None	<1% (<3 mm) → >10% (>3 mm)

Progression Logic (Exam Gold Line)

Cervical cancer progresses from lower-third dysplasia with koilocytosis → full-thickness loss of maturation → stromal invasion with desmoplasia, architectural destruction, and metastatic potential once depth exceeds 3 mm.

Ultra-Short Memory Lock

Koilocytes → gone
Maturation → lost
Basement membrane → broken
Stroma reacts → desmoplasia
Depth > 3 mm → nodes matter

🩸 Cervicitis

Very common → leukorrhea
Infectious agents:

Chlamydia trachomatis (~ 40 % STI clinic cases)
Ureaplasma urealyticum, T. vaginalis, N. gonorrhoeae, HSV-2, HPV

Herpes infection → neonatal systemic infection (if transmitted at birth)
Empiric Rx = antibiotics active vs chlamydia + gonococcus
NAAT for pathogen ID

🧬 Neoplasia of the Cervix — Pathogenesis

Most tumors = epithelial, HPV-related
Transformation zone: site where columnar → squamous metaplasia (post-puberty)
High-risk HPV (16, 18 ≫) infects immature squamous cells
Oncoproteins: E6 → inhibits p53 | E7 → inhibits RB
Other risk factors:

Early first intercourse
Multiple sexual partners
Male partner with many previous partners
Persistent high-risk HPV infection

Fig 19-4: Transformation zone illustration

🧫 Squamous Intraepithelial Lesion (SIL)

Pre-cancerous HPV-related lesion
Peaks: SIL ~30 y | Invasive Ca ~45 y
Classification (two-tier):

LSIL (CIN I) → productive HPV infection | 60 % regress | 30 % persist | 10 % progress to HSIL
HSIL (CIN II–III) → ↑ proliferation, loss of maturation | 30 % regress | 60 % persist | 10 % progress to carcinoma within ≈ 10 y

LSIL = not premalignant (→ observe)

HSIL = precancerous (→ excise / cone biopsy)

Screening: Pap smear (+ HPV DNA test ≥ 30 y)
Fig 19-6: Spectrum of SIL
Fig 19-7: Pap cytology appearance
Table 19-1: Natural history of SILs

🧠 Invasive Carcinoma of the Cervix

Types (%): Squamous ~75 | Adeno/Adenosquamous ~20 | Small-cell Neuroendocrine <5
All HPV-related
Adenocarcinoma fraction rising (less detectable by Pap)
Peak age: ~45 y (≈ 10–15 y after SIL)
Depth vs metastatic risk: < 3 mm → < 1 % nodes | > 3 mm → > 10 % nodes
Morphology: Tongues/nests of squamous cells + desmoplastic stroma ± keratin pearls
Fig 19-8: Exophytic invasive carcinoma
Clinical features: abnormal vaginal bleeding, leukorrhea, dyspareunia, dysuria
Treatment: Hysterectomy + LN dissection | Microinvasive → cone biopsy | Adjunct RT/CT as needed
Prognosis: depends on stage (+ cell type for neuroendocrine)

🩹 Endocervical Polyp

Benign polypoid mass of endocervical mucosa
Smooth, glistening surface ± mucin-filled cysts
Epithelium = mucus-secreting columnar cells
Stroma = edematous + chronic inflammation ± squamous metaplasia
May bleed but no malignant potential

UTERUS

🧫 Endometritis

Acute (neutrophils) vs chronic (lymphocytes + plasma cells).
Causes: N. gonorrhoeae, C. trachomatis (PID); tuberculous endometritis (granulomatous) esp. in TB-endemic origin or immunocompromised; retained products/IUD → ascending infection.
Clinical: fever, abdominal pain, menstrual abnormalities; ↑ risk of infertility/ectopic pregnancy.

💠 Adenomyosis

Endometrial tissue in myometrium → reactive myometrial hypertrophy → enlarged, globular uterus.
Symptoms: menorrhagia, dysmenorrhea, pelvic pain (often pre-menses); may coexist with endometriosis.

🌿 Endometriosis

Endometrial glands + stroma outside uterus; up to ~10% reproductive-age; ~50% in infertility.
Sites: pelvis (ovaries, pouch of Douglas, ligaments, tubes, rectovaginal septum) ± distant (LN, lung, heart, skeletal muscle, bone).
Origins (4): regurgitation (favored), benign metastases, metaplastic, extrauterine stem/progenitor cells.
Lesions are functioning endometrium → cyclic bleeding; ovarian cysts → “chocolate cysts.”
Dx requires both glands and stroma ectopically.

🩸 ABNORMAL UTERINE BLEEDING

🔹 Clinical Patterns

Menorrhagia – prolonged / profuse period bleeding
Metrorrhagia – irregular bleeding between periods
Post-menopausal bleeding – requires exclusion of malignancy

🔹 Major Causes

Dysfunctional uterine bleeding (DUB) – no organic lesion
Endometrial polyp • Leiomyoma • Endometrial hyperplasia / carcinoma

🔹 Mechanisms of DUB

Anovulatory cycles (MC cause) → hormonal imbalance

At menarche / perimenopause (↑ axis fluctuations)
Endocrine disorders (thyroid, adrenal, pituitary tumor)
Ovarian lesions (e.g. PCOS, granulosa cell tumor)
Metabolic states (obesity, malnutrition, chronic illness)

Inadequate luteal phase → low progesterone from corpus luteum

Table 19-2 — Causes of Abnormal Uterine Bleeding by Age Group • Prepuberty – precocious puberty (hypothalamic/pituitary/ovarian) • Adolescence – anovulatory cycles • Reproductive age – pregnancy complications (abortion, trophoblastic disease, ectopic); proliferations (leiomyoma, adenomyosis, polyps, hyperplasia, carcinoma); anovulation / luteal defect • Perimenopause – anovulation ± irregular shedding ± proliferations • Post-menopause – proliferations or endometrial atrophy

🌱 ENDOMETRIAL HYPERPLASIA

ENDOMETRIAL HYPERPLASIA — COMPLETE INTEGRATED TABLE (ZERO-OMISSION)

Domain	Hyperplasia WITHOUT Atypia	Atypical Hyperplasia / EIN
Core definition	Excess unopposed estrogen → exaggerated endometrial proliferation without cytologic atypia	Clonal neoplastic proliferation with cytologic atypia → precursor to Type I endometrioid carcinoma
Primary hormonal driver	Persistent estrogen without progesterone	Same hormonal driver PLUS genetic alterations
Common causes of estrogen excess	• Obesity (↑ aromatase in fat) • Anovulation (perimenopause, PCOS) • Exogenous estrogen therapy (no progestin) • Estrogen-producing ovarian tumors (granulosa-theca) • Tamoxifen (partial agonist)	Same causes; often long-standing / severe exposure
Pathogenesis – hormonal	Unopposed estrogen → continuous proliferation → glandular crowding	Same → selection of abnormal clone
Pathogenesis – genetic	Usually no driver mutation	PTEN loss (~50–55%) → PI3K/AKT activation → survival & proliferation
Key molecular pathway	Estrogen-driven hyperplasia	PTEN → PIK3CA → KRAS → ARID1A → MMR/MSI
WHO 2014 / 2020 category	Hyperplasia without atypia	Atypical hyperplasia / EIN
EIN diagnostic criteria	❌ Not applicable	✅ All required:• Gland > stroma (G:S >1)• Cytology different from background• Size >1 mm• Exclude mimics (polyps, repair, secretory)• No invasion
Architecture	Mild–moderate gland crowding Cystic dilation (“Swiss cheese”)	Marked glandular crowding,Complex branching, irregular outlines
Cytology	Normal columnar cells No nuclear atypia	Enlarged round nuclei, loss of polarity, coarse chromatin, nucleoli
Stroma	Abundant, intervening	Scant, compressed
Mitotic activity	Increased but orderly	Increased with abnormal forms
PTEN (IHC)	Retained	Often lost (useful diagnostic marker)
Other IHC markers	ER+, PR+, PAX8+	ER+, PR+, PAX8+
MMR status	Usually intact	May show MMR loss → consider Lynch syndrome
ARID1A	Usually intact	Mutated in subset (shared with carcinoma)
Clinical presentation	Abnormal uterine bleeding (AUB)Infertility work-up	Same; often detected on biopsy
Carcinoma coexistence	<1–3%	25–40% already have carcinoma
Progression risk	~1–3%	20–50% progression risk
Natural behavior	Often regresses with progesterone	True premalignant lesion
Management – fertility desired	Progestin therapy (oral / cyclic / LNG-IUS) + treat cause	High-dose progestin (LNG-IUS) with strict biopsy surveillance
Management – completed parity / postmenopausal	Progestin ± hysterectomy if persistent	Definitive total hysterectomy (± BSO by age)
Follow-up	Repeat biopsy every 3–6 months	Mandatory close follow-up if conservative
Relationship to carcinoma	Pre-estrogenic field change	Direct precursor to Type I endometrioid carcinoma
Stepwise pathway	Estrogen excess → hyperplasia	Estrogen → hyperplasia → EIN → carcinoma
Classic figure correlation (Fig 19-11)	A: disordered anovulatory endometrium B: hyperplasia without atypia	C: hyperplasia with atypia

One-line EXAM LOCK 🔒

Atypical hyperplasia (EIN) = clonal PTEN-driven premalignant lesion with 20–50% carcinoma risk → treat definitively unless fertility required.

🧬 ENDOMETRIAL CARCINOMA

Endometrial Carcinoma — Complete Logic-Based Comparison Table (Zero Omission)

Domain	Endometrioid Carcinoma (Type I)	Serous Carcinoma (Type II)
Overall frequency	~80% of endometrial carcinomas	~15% of endometrial carcinomas
Geographic relevance	Most common type in US & Western countries	Less common but clinically critical
Typical age group	Perimenopausal women (usually 55–65 y)	Older postmenopausal women
Occurrence before 40 y	Uncommon	Uncommon
Estrogen association	YES – strongly estrogen-dependent	NO – estrogen independent
Hormonal environment	Estrogen excess	No estrogen excess
Background endometrium	Endometrial hyperplasia	Endometrial atrophy
Pathogenetic pathway	Hyperplasia → carcinoma	Atrophy → carcinoma
Histologic resemblance	Resembles normal endometrial glands	Markedly atypical epithelium
Reason for name	“Endometrioid” due to glandular similarity	Named for serous-type morphology
Major risk factors	Obesity, diabetes, hypertension, infertility, unopposed estrogen	Not linked to classical estrogenic risk factors
Mechanism behind risk factors	All → ↑ estrogenic stimulation → hyperplasia	Not hormone driven
Exogenous estrogen risk	Prolonged estrogen replacement therapy ↑ risk	No association
Ovarian tumor association	Estrogen-secreting ovarian tumors ↑ risk	No association
Key early molecular events	PTEN mutation, DNA mismatch repair (MMR) gene mutations	TP53 mutation (early and universal)
Late molecular events	TP53 mutation (uncommon, late)	—
Inherited syndromes	Cowden syndrome (PTEN), Lynch syndrome (MMR)	Not characteristically associated
Precursor lesion	Endometrial hyperplasia (esp. atypical)	Serous Endometrial Intraepithelial Carcinoma (SEIC)
Role of TP53	Late, relatively uncommon	Early, near-universal
Gross growth pattern	Exophytic or infiltrative	Often subtle, papillary
Microscopic architecture	Glandular patterns resembling normal endometrium	Small tufts, papillae, may form glands
Cytologic atypia	Mild–moderate (grade-dependent)	Marked cytologic atypia
Histologic variants	Mucinous, tubal (ciliated), squamous differentiation	Limited differentiation patterns
Myometrial invasion	Common	Common and often deep
Lymphovascular invasion	May occur	Frequent
Regional lymph node spread	Possible	Common
Tumor grading	Grade 1–3 (based on differentiation)	Always high-grade by definition
Immunohistochemistry	Variable p53 staining	Diffuse, strong p53 positivity
p53 staining mechanism	—	Mutant p53 accumulates → detectable
Biologic behavior	Relatively indolent	Highly aggressive
Typical clinical presentation	Irregular or postmenopausal bleeding	Same presentation
Uterine changes with progression	Uterine enlargement	Uterine enlargement
Local tissue infiltration	Occurs with progression	Early and extensive
Fixation to surrounding structures	Late	Common
Metastatic tendency	Slow if untreated	Early and rapid
Stage at presentation	Often early stage	Often high stage
5-year survival (early stage)	≈ 90%	Lower even when treated
Effect of advancing stage	Survival drops sharply	Poor prognosis overall
Dependence on operative staging	Important	Critical for prognosis
Overall prognosis	Generally favorable if early	Generally poor

One-Line Exam Lock (optional memory anchor)

Endometrioid = estrogen + hyperplasia + PTEN/MMR + graded
Serous = atrophy + TP53 + always high-grade + aggressive

EXAM-LOCK SUMMARY (ONE-GLANCE)

Type I = Estrogen + Hyperplasia + PTEN + Better prognosis
Type II = p53 + Atrophic endometrium + Aggressive
Serous carcinoma behaves like ovarian serous cancer
Carcinosarcoma = carcinoma with sarcomatous disguise
Depth of myometrial invasion = strongest prognostic factor

🌿 ENDOMETRIAL POLYPS

Sessile 0.5–3 cm, may project into cavity.
Endometrium resembles basalis layer; thick-walled arteries.
Glands: normal → cystic dilation.
Stroma: monoclonal cells with 6p21 rearrangement (neoplastic component).
Age: perimenopausal common.
Clinical: abnormal bleeding; benign.

💪 LEIOMYOMA ( = Uterine Fibroid )

Most common benign tumor in women (30 – 50 %); ↑ in Black women.
Origin: myometrial smooth muscle.
Genetics: recurrent chr 6 / 12 rearrangements + MED12 mutation (~ 70 %).
Hormonal dependence: ↑ with estrogen / OCP; ↓ post-menopause.
Morphology (Fig 19-13): sharply circumscribed gray-white whorled masses; single or multiple (intramural, submucosal, subserosal).
Clinical: menorrhagia, pelvic mass effect, infertility (if cavity distortion); no malignant potential.

⚠️ LEIOMYOSARCOMA

Malignant smooth-muscle tumor (arises de novo).
Gross = soft, bulky, hemorrhagic/necrotic.
Micro = spindle cell atypia + high mitotic index.
Behavior: frequent recurrence + lung/brain metastases → poor prognosis.

Absolutely — picking up where we left off and restarting the remaining sections with MICRO-AUDITS, still point-form and Breast excluded.

🧬 FALLOPIAN TUBES

Serous Tubal Intraepithelial Carcinoma (STIC)

Earliest precursor for many “ovarian” high-grade serous carcinomas.
Genetics: TP53 mutations in >90%.
Epidemiology/setting: often found in prophylactic salpingo-oophorectomy specimens from BRCA1/BRCA2 carriers.
Site: fimbrial end; plausible seeding to ovarian/peritoneal surfaces.

Endometrial Polyps vs Leiomyoma vs Leiomyosarcoma — Complete Comparison Table

Feature	Endometrial Polyps	Leiomyoma (Fibroid)	Leiomyosarcoma
Nature	Benign endometrial lesion	Benign smooth muscle tumor	Malignant smooth muscle tumor
Cell of Origin	Endometrial stromal cells (neoplastic component)	Smooth muscle cells of myometrium	Mesenchymal cells of myometrium
Neoplastic Component	Stroma is monoclonal	Smooth muscle cells	Malignant smooth muscle cells
Genetics / Molecular	Rearrangement of chromosomal region 6p21	Recurrent chromosomal rearrangements of chromosomes 6 & 12; MED12 mutations (up to 70%)	No precursor lesion; arises de novo
Hormonal Influence	Not emphasized	Estrogen-dependent growth; stimulated by estrogens ± OCPs; shrink postmenopause	Not estrogen dependent
Typical Age Group	Any age, most common around menopause	Reproductive age	Postmenopausal
Incidence / Frequency	Common	Most common benign tumor in females (30–50%)	Rare
Ethnic Predilection	Not specified	More common in black women	Not specified
Number of Lesions	Usually single	Often multiple	Almost always solitary
Size	0.5 – 3 cm	Variable: small nodules → very large masses	Variable, often large
Gross Appearance	Sessile; larger polyps may project into uterine cavity	Firm, gray-white, sharply circumscribed, whorled cut surface	Soft, hemorrhagic, necrotic
Location	From endometrial mucosa, may protrude into cavity	Intramural, submucosal, subserosal	Within myometrium
Special Gross Variants	—	Parasitic leiomyomas (pedunculated, attached to surrounding organs with new blood supply)	—
Histologic Glands	Some normal; more often cystically dilated	—	—
Histology (Cells)	Endometrium resembling basalis; small muscular arteries	Bundles of smooth muscle resembling normal myometrium	Variable: well-differentiated → wildly anaplastic
Degenerative Changes	—	Fibrosis, calcification, degenerative softening	Hemorrhage & necrosis
Clinical Presentation	Abnormal uterine bleeding	Often asymptomatic; menorrhagia ± metrorrhagia	Rapid growth, postmenopausal mass, systemic effects
Discovery	Symptomatic bleeding or incidental	Often incidental on pelvic exam	Symptomatic
Malignant Potential	Benign	Rarely, if ever, transform; multiplicity ≠ ↑ risk	Frankly malignant
Recurrence	—	—	Common after surgery
Metastasis	—	—	Common, especially to lungs
Prognosis	Excellent	Excellent	Poor
5-Year Survival	—	—	~40%
Special Diagnostic Category	—	—	STUMP (Smooth muscle tumor of uncertain malignant potential)
Key Diagnostic Criteria (Histology)	Monoclonal stroma	Benign smooth muscle	Triad required: tumor necrosis + cytologic atypia + mitotic activity
Diagnostic Pitfall	—	High mitotic activity may occur in benign tumors (young women)	Mitotic count alone is insufficient

Ultra-High-Yield Exam Locks 🔒

Endometrial polyp = monoclonal stroma + cystically dilated glands + AUB
Leiomyoma = estrogen-dependent, whorled, multiple, benign
Leiomyosarcoma = de novo, solitary, postmenopausal, necrosis + atypia + mitoses
Fibroids ≠ sarcoma risk
Rapid growth postmenopause → think sarcoma

Fallopian Tube Disorders — Complete Integrated Table (Zero Omission)

Domain	Aspect	Details (Logic + Exam-Safe)
Epidemiology	Most common disorder	Inflammation (salpingitis)
	Clinical context	Almost always part of Pelvic Inflammatory Disease (PID)
Less common disorders	Other tubal abnormalities	Ectopic (tubal) pregnancy, endometriosis
Etiology of salpingitis	Fundamental cause	Almost always infectious
Sexually transmitted organisms	Classic PID pathogens	Neisseria gonorrhoeae, Chlamydia trachomatis
Nongonococcal organisms	Important contributors	Chlamydia, Mycoplasma hominis, coliforms
Postpartum infections	Typical organisms	Streptococci, Staphylococci
Gonococcal infection	Morphologic pattern	Similar to male genital tract gonococcal infection
Coliform / streptococcal / staphylococcal infection	Tissue behavior	Penetrate tubal wall
	Systemic consequence	Can cause blood-borne (hematogenous) spread to distant sites
Tuberculous salpingitis	Frequency	Rare
	Association	Almost always with tuberculous endometritis
Clinical features (all types)	Systemic symptoms	Fever
	Pain	Lower abdominal pain, pelvic pain
	Pelvic findings	Pelvic mass
Cause of pelvic mass	Pathophysiology	Distension of fallopian tubes by exudate or inflammatory debris
Local spread of inflammation	Adhesions	Inflamed tube adheres to ovary and adjacent ligamentous tissues
Severe complication	Tubo-ovarian abscess	Adhesion between tube + ovary → tubo-ovarian abscess
Healing phase	Residual damage	Adhesions persist between ovary and tubes
Tubal plicae involvement	Critical sequela	Adhesions of tubal plicae
Major reproductive risk	Ectopic pregnancy	Plicae adhesions → ↑ risk of tubal ectopic pregnancy
Luminal damage	Fertility impact	Obstruction or damage of tubal lumen → permanent sterility
Fallopian tube carcinoma	Old concept	Primary adenocarcinoma considered rare
Current understanding	New paradigm	Many high-grade serous “ovarian” carcinomas originate in fallopian tube
Precursor lesion	Name	Serous Tubal Intraepithelial Carcinoma (STIC)
STIC location	Anatomy	Fimbriated end of fallopian tube
STIC genetics	Molecular feature	TP53 mutation in >90% of cases
Genetic risk population	High-risk groups	Frequently found in BRCA1 / BRCA2 mutation carriers
Prophylactic surgery finding	Evidence	STIC found in prophylactically removed tubes
Sporadic cancer link	Broader implication	Also found (less commonly) in women without known genetic risk
Tumor origin concept	Key idea	Many sporadic “ovarian” serous carcinomas originate in tube
Anatomical explanation for spread	Fimbrial anatomy	Fimbriated end is intimately associated with ovary
	Peritoneal access	Tube has direct access to peritoneal cavity
Pattern of spread at presentation	Sites involved	Ovary, omentum, peritoneal cavity
Clinical implication	Disease stage	Often advanced disease at presentation

Ultra-High-Yield Exam Locks

Most common tubal disorder → salpingitis (PID)
Postpartum salpingitis → streptococci + staphylococci
Plicae adhesions → ectopic pregnancy
Luminal damage → permanent sterility
High-grade serous “ovarian” cancer → often tubal origin
STIC + TP53 + BRCA = exam gold

🥚 OVARIES

TUMORS OF THE OVARY — COMPLETE MASTER TABLE (ZERO OMISSION)

I. OVERVIEW & ORIGIN

Feature	Details
Annual burden (US, 2016)	>20,000 cases; >14,000 deaths
Rank in female cancer mortality	5th leading cause
Cell of origin (3 types)	1️⃣ Surface (coelomic) epithelium 2️⃣ Germ cells 3️⃣ Sex cord–stromal cells
Most common origin	Surface epithelial tumors
% of ovarian tumors	Epithelial ≈ majority
% of ovarian cancers	≈ 90% epithelial
Germ cell + sex cord tumors	20–30% of tumors, <10% malignant

II. SURFACE EPITHELIAL TUMORS — GENERAL FEATURES

Feature	Details
True origin (modern view)	Many arise from fimbrial end of fallopian tube
Cortical cyst epithelium	From displaced ovarian surface epithelium or tubal epithelium
Pathogenesis	Metaplasia → neoplasia
Benign forms	Cystadenoma ± cystadenofibroma
Malignant forms	Cystadenocarcinoma (cystic) or carcinoma (solid)
Borderline tumors	Intermediate behavior; recur; may progress
Risk factors	Nulliparity, family history
Protective factor	Prolonged oral contraceptive use
Familial cases	5–10%
Key genes (familial)	BRCA1, BRCA2
Lifetime ovarian cancer risk	BRCA1 ≈ 30%; BRCA2 lower
Sporadic tumors	BRCA mutations in only 8–10%

III. SERIOUSLY HIGH-YIELD: SURFACE EPITHELIAL SUBTYPES

A. SEROUS TUMORS

Feature	Details
Frequency	Most common ovarian tumor overall
Benign	~60%
Borderline	~15%
Malignant	~25%
Benign age group	30–40 years
Malignant age group	45–65 years

Low-Grade vs High-Grade Serous Carcinoma

Feature	Low-Grade	High-Grade
Origin	Benign / borderline lesions	STIC in fimbrial fallopian tube
Progression	Slow, stepwise	Rapid
Key mutations	KRAS, other signaling genes	TP53 (>95%), NF1, RB
BRCA association	Uncommon	Common in familial cases
Aggressiveness	Lower	Very high

Morphology — Serous Tumors

Aspect	Features
Gross size	Large, spherical/ovoid
Diameter	Up to 30–40 cm
Bilaterality (benign)	~25%
Benign surface	Smooth, glistening
Malignant surface	Nodular irregularities (serosal invasion)
Cut section	Uni- or multiloculated cysts
Contents	Clear serous fluid
Papillae	Present; more prominent in malignancy

Histology-Serous tumors

Tumor Type	Microscopic Features
Benign	Single layer ciliated columnar cells
Psammoma bodies	Common
Borderline	Mild atypia, no stromal invasion, may seed peritoneum
High-grade carcinoma	Marked atypia, complex papillae, stromal invasion

Spread & Prognosis

Feature	Details
Spread	Peritoneal cavity, para-aortic LN
Distant mets	Rare
Stage I survival	~90%
Advanced stage survival	<40%
Borderline tumors	≈ 100% survival
BRCA tumors	Better prognosis

B. MUCINOUS TUMORS

Feature	Details
Epithelium	Mucin-secreting
Benign	~80%
Borderline	~10%
Malignant	~10%
KRAS mutation	~50%
Prognosis	Better than serous
Major determinant	Stage, not histology

Morphology-Mucinous tumors

Feature	Details
Gross	Very large, multicystic
Contents	Mucin
Bilaterality	Uncommon
Malignancy clues	Solid areas, serosal penetration
Histology	Stratification, atypia, stromal invasion

Special Associations-Mucinous tumors

Condition	Notes
Krukenberg tumor	GI metastases → bilateral ovaries
Pseudomyxoma peritonei	Usually appendiceal origin
Rupture	Peritoneal seeding (often regresses)

C. ENDOMETRIOID TUMORS

Feature	Details
Architecture	Tubular glands (endometrial-like)
Association	Endometriosis
Behavior	Usually malignant
Bilaterality	~30%
Concomitant endometrial CA	15–30%
Key genes	PTEN, PI3K-AKT pathway

D. BRENNER TUMOR

Feature	Details
Frequency	Rare
Laterality	Usually unilateral
Gross	Solid, gray-white, encapsulated
Size	Few cm → 20 cm
Histology	Transitional-type epithelium
Possible origin	Surface epithelium or trapped urogenital epithelium
Behavior	Mostly benign; borderline/malignant rare

IV. GERM CELL TUMORS

TERATOMAS (15–20% of ovarian tumors)

A. BENIGN (MATURE) CYSTIC TERATOMA

Feature	Details
Age	Young women
Layers present	Ectoderm, mesoderm, endoderm
Common name	Dermoid cyst
Laterality	90% unilateral (right > left)
Size	Usually <10 cm
Gross	Sebum, hair, teeth
Complications	Torsion (10–15%), infertility
Paraneoplastic	Limbic encephalitis
Malignant transformation	~1% (usually SCC)

B. IMMATURE (MALIGNANT) TERATOMA

Feature	Details
Mean age	18 years
Gross	Bulky, solid, necrotic
Histology	Immature cartilage, bone, muscle, nerve
Prognosis	Grade + stage dependent

C. SPECIALIZED TERATOMAS

Type	Key Feature
Struma ovarii	Thyroid tissue → hyperthyroidism
Ovarian carcinoid	Rare carcinoid syndrome

V. SALIENT FEATURES — OTHER OVARIAN NEOPLASMS

GERM CELL & SEX CORD–STROMAL TUMORS

Tumor	Age	Laterality	Key Morphology	Behavior
Dysgerminoma-Germ cell	2nd–3rd decade	Unilateral	Clear cells, lymphocytes	Malignant, radiosensitive
Choriocarcinoma-Germ cell	Young	Unilateral	Cytotrophoblast + syncytiotrophoblast	Early widespread mets
Granulosa-theca	Postmenopausal	Unilateral	Call-Exner bodies	Estrogenic
Thecoma-fibroma	Any	Unilateral	Yellow lipid cells	Meigs syndrome
Sertoli-Leydig	Any	Unilateral	Testis-like cords	Masculinizing
Metastases	Older	Bilateral	Signet-ring cells(krukenberg)	GI, breast, lung

VI. CLINICAL FEATURES & MARKERS

Feature	Details
Early symptoms	Usually absent
Common presentation	Large mass, pressure symptoms
Ascites	Malignant serous tumors
Torsion	Dermoid cysts
Functional tumors	Endocrinopathies
Screening	Poor
CA-125	↑ in 75–90% epithelial tumors
Limitation	Poor early detection
Best use	Monitoring therapy response

Type I vs Type II Ovarian Tumors — Exam Table

Exam feature	Type I (Slow / Stepwise / “Low-grade pathway”)	Type II (Fast / Aggressive / “High-grade pathway”)
Big idea	Indolent, develops step-by-step from a recognizable precursor	Highly aggressive, develops rapidly, often de novo
Typical stage at diagnosis	Often earlier stage (I–II)	Often advanced stage (III–IV)
Growth & spread	Slower growth; more localized early	Rapid growth; early peritoneal spread/ascites
Genomic pattern	Relative genetic stability	Marked genomic instability
Prototype tumor	Low-grade serous carcinoma	High-grade serous carcinoma (HGSC) (the big one)
Common histologies included	Low-grade serous, mucinous, endometrioid (low-grade), clear cell (often grouped here), malignant Brenner (rare)	HG serous, undifferentiated carcinoma, carcinosarcoma (MMMT) (± some high-grade endometrioid in some schemes)
Precursor lesion	Often arises from benign/borderline tumors (e.g., serous borderline → low-grade serous)	Often arises from STIC (Serous Tubal Intraepithelial Carcinoma) in fimbrial tube
Site of origin (concept)	More “ovary/cortical inclusion cyst” pathway (traditional teaching)	More “fallopian tube fimbria” origin (STIC → HGSC)
Key driver gene theme	Oncogene-pathway mutations (signal transduction)	TP53-centered pathway ± DNA repair failure
Typical mutations (high-yield)	KRAS, BRAF, ERBB2(HER2) (esp mucinous), PTEN, PIK3CA, ARID1A, CTNNB1 (β-catenin) (esp endometrioid/clear cell groups)	TP53 (vast majority of HGSC), BRCA1/BRCA2 (germline or somatic), other homologous recombination genes
p53 IHC clue	Often wild-type pattern (unless unusual)	Often abnormal p53 pattern (mutation pattern)
Borderline tumor link	Strong link (esp serous borderline → low-grade serous)	No borderline stage typically
Typical patient profile	Slightly younger than Type II (varies by subtype)	Often older, postmenopausal tendency
Chemosensitivity	Often less chemo-responsive (because slower-growing); surgery important	Often more chemo-responsive initially (platinum-based) but high relapse risk
Prognosis (overall)	Generally better (because earlier stage + indolent)	Generally worse (advanced stage + aggressive biology)
One-line memory hook	“Type I = I for Indolent, Increments (stepwise)”	“Type II = Too aggressive, TP53, Tubal (STIC)”

Ultra-fast recall (1-liners)

Type I: Borderline/benign precursor → stepwise → KRAS/BRAF/PTEN/PIK3CA/ARID1A
Type II: STIC (fimbria) → HGSC → TP53 ± BRCA → widespread peritoneal disease

Note-

1) Follicular & Luteal Cysts (Functional cysts = near-normal physiology)

Why they happen

From unruptured Graafian follicle OR follicle ruptures then immediately seals.

Where / how they look

Often multiple, just under ovarian serosa (subserosal/subjacent).
Usually small: 1–1.5 cm, filled with clear serous fluid.

When they matter clinically

Can enlarge to 4–5 cm → palpable mass + pelvic pain.
Lining: early granulosa cells (follicular cyst) or luteal cells (luteal cyst).
As fluid ↑ → pressure → atrophy of lining cells.

Complication

Rupture → intraperitoneal bleeding → peritoneal irritation → acute abdomen picture.

2) Polycystic Ovarian Syndrome (PCOS / Stein-Leventhal)

Core syndrome (definition bundle)

Hyperandrogenism + menstrual abnormalities + polycystic ovaries + chronic anovulation + ↓ fertility.

Typical presentation

Often noticed after menarche (teens/young adults):

Oligomenorrhea, hirsutism, infertility, ± obesity.

Gross ovary

Ovaries about 2× normal size, gray-white, smooth outer cortex
Subcortical cysts: 0.5–1.5 cm.

Histology (high-yield “why it looks like that”)

Thickened fibrotic capsule
Innumerable cystic follicles lined by granulosa cells
Hyperplastic luteinized theca interna
Absent corpora lutea → fits chronic anovulation.

3) Ovarian Tumors: big framework

Why ovarian tumors are so varied

Can arise from 3 normal ovarian cell sources:

Surface (coelomic) epithelium (incl. cortical epithelial cysts / tubal-type epithelium)
Germ cells (totipotent)
Sex cord–stromal cells

Epithelial tumors dominate

Great majority of ovarian tumors.
Malignant epithelial tumors account for ~90% of ovarian cancers.
Germ cell + sex cord–stromal tumors: 20–30% of ovarian tumors, but <10% of malignant ovarian tumors.

4) Surface epithelial tumors: origin + categories

Modern concept of origin

Many “ovarian” epithelial cancers actually arise from fimbrial end of fallopian tube (not true ovarian surface).
Ovarian cortical epithelial cysts may come from displaced ovarian surface epithelium or tubal epithelium → metaplasia / neoplastic transformation.

Category ladder

Benign: usually cystic = cystadenoma (± stromal component = cystadenofibroma)
Malignant: cystadenocarcinoma (cystic) or carcinoma (solid)
Borderline tumors: intermediate; mostly benign behavior but can recur, some progress to carcinoma.

5) Ovarian cancer risk factors (must-remember exam set)

Higher risk

Nulliparity / low parity, family history, germline tumor suppressor mutations.
Higher incidence in unmarried and married with low parity.

Protective

Prolonged oral contraceptive use ↓ risk.

Familial / BRCA

5–10% ovarian cancers are familial, mostly BRCA1/BRCA2.
Lifetime ovarian cancer risk:

BRCA1 ~30%
BRCA2 lower than BRCA1

In sporadic ovarian cancers: BRCA1/2 mutations only ~8–10% → many arise via other mechanisms.

6) Serous Tumors (most common epithelial; biggest malignant fraction)

Frequency split

60% benign, 15% borderline, 25% malignant.

Age

Benign: 30–40 yrs
Malignant: 45–65 yrs

Two carcinoma pathways

Low-grade serous carcinoma

Slow, stepwise progression from benign/borderline lesions
Often KRAS (signaling pathway genes)

High-grade serous carcinoma

Rapid development
Often from fimbrial tube via serous tubal intraepithelial carcinoma (STIC)
TP53 mutation >95% (virtually universal)
Other common: NF1, RB; BRCA1/2 in familial cases

Morphology

Often large, cystic, 30–40 cm, spherical/ovoid.
Bilateral: ~25% of benign serous tumors.
Benign: smooth, glistening surface.
Malignant: nodular irregularities where tumor invades serosa.
Cut section: unilocular or multiloculated (septa), clear serous fluid, papillary projections (more prominent in malignant).
Histology:

Benign: single layer columnar, often ciliated
Psammoma bodies common (calcified laminated bodies) at papilla tips
High-grade malignant: marked atypia, complex multilayered papillae, stromal invasion
Borderline: less atypia, no stromal invasion, may seed peritoneum but usually noninvasive implants

Spread

Malignant serous tumors: spread widely in peritoneal cavity + regional nodes (periaortic).
Distant blood spread less common.

Prognosis

High-grade: generally poor, strongly stage-dependent.
5-yr survival:

Confined to one ovary ~90%
Higher stages: <40% (depends on stage)

Borderline tumors: ~100% survival
BRCA1/2-mutated tumors often have better prognosis than non-mutated.

7) Mucinous Tumors

Key differences vs serous

Lining epithelium is mucin-secreting
Much less likely malignant

Frequency

80% benign, 10% borderline, 10% malignant

Morphology

Usually larger, often multicystic; contents are mucinous.
Serosal penetration + solid areas → suggest malignancy.
Malignancy histology: stratification/piling up, atypia, stromal invasion.

Bilateral?

Much less likely bilateral than serous.
Helps differentiate from metastatic GI mucinous adenocarcinoma (often bilateral) → classic example: Krukenberg tumor.

Peritoneal issues

Rupture may seed peritoneum but often regress.
Persistent mucin implants with lots of mucin = pseudomyxoma peritonei (most often from GI tract, especially appendix).

Genetics

KRAS mutations ~50% in ovarian mucinous carcinoma (not helpful to separate from GI metastases—GI primaries also commonly KRAS).

Outcome

Somewhat better than serous, but stage > histologic type for prognosis.

8) Endometrioid Tumors

Can be solid or cystic, sometimes linked with endometriosis.
Microscopy: tubular glands like endometrium lining cystic spaces.
Usually malignant (though benign/borderline exist).
Bilateral ~30%.
15–30% have concomitant endometrial carcinoma.
Genetics: often PTEN mutations + other changes activating PI3K-AKT.

9) Brenner Tumor

Uncommon, solid, usually unilateral.
Lots of stroma with nests of transitional-type epithelium (urinary-tract like).
Sometimes nests become cystic and lined by columnar mucin-secreting cells.
Encapsulated, gray-white, size from few cm to 20 cm.
Possible origin: surface epithelium or trapped urogenital epithelium in germinal ridge.
Mostly benign, but borderline/malignant described.

10) Teratomas (germ cell; high-yield clinical)

15–20% of ovarian tumors.
Often occur in first 2 decades; younger age = higher malignancy risk, BUT:

>90% are benign mature cystic teratomas (dermoid cysts)
Immature malignant teratoma is rare

A) Mature cystic teratoma (dermoid)

Mature tissues from ectoderm + endoderm + mesoderm.
Often: cyst lined by epidermis with adnexal appendages.
Found in young women; may be incidental (imaging shows calcification/toothlike structures).
~90% unilateral, right > left.
Usually <10 cm.
Cut section: sebaceous material + hair; may have teeth, sometimes bone/cartilage, bronchial/GI epithelium, etc.
Clinical issues:

Can cause infertility
Torsion 10–15% → acute emergency
Rare paraneoplastic: limbic encephalitis (esp. if mature neural tissue) → may remit after resection
Malignant transformation ~1%, usually squamous cell carcinoma

B) Immature malignant teratoma

Mean age ~18 yrs.
Bulky, solid, often necrosis; may have cystic foci.
Microscopy: immature elements / minimally differentiated cartilage, bone, muscle, nerve, etc.
Prognosis depends on grade + stage.

C) Specialized teratomas

Struma ovarii: thyroid tissue only → may cause hyperthyroidism.
Ovarian carcinoid: rarely causes carcinoid syndrome.

11) Clinical features + screening reality

Why they’re dangerous: many are silent until advanced.
Symptoms when large:

Pressure symptoms: pain, GI complaints, urinary frequency
↑ abdominal girth with big epithelial tumors

Torsion: more with smaller masses like dermoid cyst → severe pain mimics acute abdomen.
Ascites: often with malignant serous tumor peritoneal seeding.
Functioning tumors: present via endocrinopathies.
Treatment: still not ideal, only modest survival gains since mid-1970s.
CA-125

Elevated in 75–90% epithelial ovarian cancers.
But up to 50% of cancers confined to ovary have normal/undetectable CA-125.
Also elevated in many benign conditions + non-ovarian cancers.
Best use: monitoring treatment response.

12) Other important ovarian tumors (table facts that examiners pick)

Dysgerminoma

2nd–3rd decade; unilateral 80–90%
Testicular seminoma counterpart; malignant but only ~1/3 metastasize
Radiosensitive, ~80% cure

Choriocarcinoma (ovary)

Early decades; metastasizes early and widely
Primary may regress → only metastases found
Resistant to chemotherapy

Granulosa-theca cell tumor

Often postmenopausal; can be any age; unilateral
Can produce lots of estrogen
Granulosa part malignant 5–25%

Thecoma-fibroma

Often hormonally inactive; rarely malignant
~40% with Meigs syndrome (ascites + hydrothorax)

Sertoli-Leydig cell tumor

Any age; many cause masculinization/defeminization; rarely malignant

Metastases to ovary

Older age; mostly bilateral
Primaries: GI tract (Krukenberg), breast, lung
Can show signet ring mucin-secreting cells

Diseases of pregnancy

Gestational Trophoblastic Disease (GTD) + Preeclampsia/Eclampsia — Complete Integrated Table

A. Gestational Trophoblastic Disease (GTD)

Domain	Complete Hydatidiform Mole	Partial Hydatidiform Mole	Invasive Mole	Choriocarcinoma	Placental Site Trophoblastic Tumor (PSTT)
WHO Category	Molar	Molar	Molar (locally invasive)	Non-molar	Non-molar
Core Pathogenesis	Excess paternal genome only → unchecked trophoblast	Excess paternal genome with maternal contribution	Complete mole with deep myometrial invasion	Malignant trophoblast with early vascular invasion	Neoplasm of intermediate trophoblast
Fertilization / Genetics	Diploid 46,XX (most) or 46,XY; all paternal (empty egg + 2 sperm or diploid sperm)	Triploid 69,XXY (most); normal egg + 2 sperm	Same as complete mole	Variable; gestational or germ-cell origin	Diploid, often XX
Embryo / Fetal Parts	Absent	May be present	Absent	Absent	Absent
Chorionic Villi	All villi abnormal (hydropic)	Mixed normal + abnormal villi	Present and hydropic	Absent	Absent
Trophoblast Proliferation	Diffuse (cyto + syncytio)	Focal, mild	Marked	Marked, anaplastic	Intermediate trophoblast
Gross Appearance	Grapelike, cystic villi filling uterus	Similar but less diffuse	Invasive, destructive	Hemorrhagic, necrotic masses	Often nodular at placental site
β-hCG Level	Very high	Elevated (less than complete)	Persistently elevated	Extremely high	Low–mild elevation
Other Hormone	—	—	—	—	hPL ↑
Uterine Size	Enlarged, classically “large for dates”	Mild enlargement	Enlarged, invasive	Not markedly enlarged	Variable
Clinical Clues	No FHS, high hCG	Possible fetal tissue	Persistent bleeding, invasion	Brown/bloody discharge, high hCG	Months after pregnancy, low hCG
Metastasis	No	No	No true metastasis (embolized villi may regress)	Early hematogenous spread	Occurs late
Common Spread Sites	—	—	—	Lung (50%), vagina (30–40%), brain, liver, kidney	Beyond uterus = poor prognosis
Chemo Sensitivity	High (if needed)	Rarely needed	Very good	Excellent (≈100% cure)	Poor
Prognosis	Excellent	Excellent	Excellent with chemo	Excellent (placental type)	Good if uterine-confined
Progression Risk	~10% invasive; 2–3% choriocarcinoma	Very low	—	Aggressive but curable	Poor once extra-uterine

B. Epidemiology & Risk Pattern (Moles)

Feature	Details
Incidence (Complete Mole)	1–1.5 / 2000 pregnancies (West)
Geographic Pattern	Higher in Asian countries
Age Risk	<20 yrs and >40 yrs
Recurrence Risk	Increased after prior mole
Detection Trend	Earlier now due to routine ultrasound

C. Monitoring & Management Logic (All GTD)

Principle	Clinical Meaning
Universal Marker	β-hCG
Diagnosis	Abnormally high hCG
Follow-up	Serial hCG until undetectable
Outcome Prediction	hCG trend > histologic grading
Persistent Disease	Rising/plateau hCG → chemo
Cure Rates	Very high with correct monitoring

D. Preeclampsia / Eclampsia — Mechanism-First Table

1. Definitions

Term	Definition
Preeclampsia	HTN + proteinuria ± edema after mid-pregnancy
Eclampsia	Preeclampsia + seizures
Incidence	5–10% of pregnancies
High-Risk Groups	First pregnancy, age >35
Old Term	“Toxemia of pregnancy” (incorrect)

2. Core Pathogenesis (Single Root Cause)

Step	Pathologic Event	Consequence
1	Inadequate spiral artery remodeling	Narrow, high-resistance vessels
2	Reduced uteroplacental flow	Placental hypoxia
3	Placental dysfunction	Release of anti-angiogenic factors
4	↑ sFlt-1, sEng; ↓ VEGF	Endothelial dysfunction
5	Systemic vasculopathy	Multisystem disease

3. Major Clinical Consequences

System	Mechanism	Outcome
Blood Pressure	↓ prostacyclin/PGE₂, ↑ TXA₂	Hypertension
Coagulation	Endothelial damage + tissue factor	Hypercoagulability
Kidney	Endothelial injury	Proteinuria, renal failure
Liver	Microangiopathy	Elevated enzymes
Placenta	Hypoperfusion	Infarction, abruption

4. HELLP Syndrome

Component	Mechanism
Hemolysis	Microangiopathic
Elevated Liver Enzymes	Hepatic endothelial injury
Low Platelets	Consumption ± DIC
Frequency	~10% of severe preeclampsia

5. Morphology

Placenta

Finding	Significance
Multiple infarcts	Chronic hypoperfusion
Retroplacental hemorrhage	Severe disease
Premature villous maturation	Placental stress
Syncytial knots ↑	Hypoxia marker

Decidual Vessels

Lesion	Meaning
Fibrinoid necrosis	Severe vascular injury
Acute atherosis	Lipid-laden macrophages

6. Clinical Course Rule (Exam Gold)

Rule	Implication
Early treatment	Prevents organ damage
Delivery	Disease resolves
Delay	Risk of eclampsia, HELLP

One-Line Exam Anchors

GTD management is guided by β-hCG trend, not histology.
Choriocarcinoma: no villi, early blood spread, chemo-curable.
PSTT: low hCG, hPL positive, surgery-dominant management.
Preeclampsia = failed spiral artery remodeling → endothelial dysfunction → multisystem disease.

1) Gestational Trophoblastic Disease (GTD) — core idea

Definition: Abnormal proliferation of fetal trophoblast cells.
Why the umbrella term matters clinically: What predicts response and guides management best is hormone behavior (hCG trend) more than fine pathology subtyping.
Shared biochemical hallmark: All GTD lesions elaborate hCG, detectable in blood/urine at levels higher than normal pregnancy.

Diagnosis: unusually high hCG helps suspect GTD.
Monitoring: serial β-hCG is used to track treatment efficacy and detect persistent disease/relapse.

2) WHO classification — the map

A) Molar lesions

Complete hydatidiform mole
Partial hydatidiform mole
Invasive hydatidiform mole (locally invasive form, typically from complete mole)

B) Nonmolar lesions

Choriocarcinoma
Other uncommon trophoblast-derived malignancies (includes placental site trophoblastic tumor discussed later)

3) Hydatidiform mole (general picture)

Gross “look”: Uterus filled with swollen, cystically dilated chorionic villi → looks like grapelike clusters.
Surface lining: swollen villi are covered by chorionic epithelium showing variable atypia (from normal → highly atypical).

4) Complete vs Partial mole — logic from fertilization → genetics → phenotype

A) Shared mechanism

Both result from abnormal fertilization with excess paternal genetic material (paternal genome predominance drives trophoblastic proliferation).

B) Complete hydatidiform mole

Genetics / formation

Diploid: usually 46,XX, less commonly 46,XY.
All genetic content is paternal:

A typical mechanism is an “empty” egg + two sperm (or one diploid sperm) → diploid conceptus with only paternal chromosomes.

Embryo/fetus

Not compatible with embryogenesis
Rarely contains fetal parts

Villi

All chorionic villi are abnormal

C) Partial hydatidiform mole

Genetics / formation

Triploid: almost always 69,XXY (example given).
Mechanism: a normal egg fertilized by two sperm (or a diploid sperm) → triploid with preponderance of paternal genes.

Embryo/fetus

Compatible with early embryo formation
May contain fetal parts (and often does)

Villi

Some normal chorionic villi remain (mixture of normal + abnormal)

5) Epidemiology + risk pattern + how we find it now

Incidence (complete mole): about 1 to 1.5 per 2000 pregnancies in the US/Western countries.
Higher incidence in Asian countries (reason stated as unknown).
Age risk: more common <20 years and >40 years.
Recurrence risk: history of molar disease increases risk in subsequent pregnancies.
Detection shift: Previously discovered around 12–14 weeks when uterus was “too large for dates”; now earlier due to routine ultrasound monitoring.

6) Clinical pattern of complete/partial moles (what you expect at bedside)

hCG elevated in maternal blood
Absent fetal heart sounds (typical)
Follow-up outcomes after evacuation:

80–90% do not recur after thorough curettage.
~10% of complete moles become invasive.
2–3% (max) progress to choriocarcinoma.

7) Morphology (moles) — what pathology shows, and why grading is outdated

Gross (advanced cases)

Uterine cavity expanded by a delicate, friable mass of thin-walled, translucent cystic structures.
Fetal parts

Rare in complete moles
Common in partial moles

Microscopy — complete mole

Hydropic swelling of poorly vascularized chorionic villi
Loose, myxomatous, edematous stroma
Trophoblast proliferation: both

Cytotrophoblasts
Syncytiotrophoblasts

Microscopy — partial mole

Villous edema involves only a subset of villi
Trophoblast proliferation: focal and slight
Fetal cells often present

can be as minimal as fetal red cells in villi
rarely can include a fully formed fetus

Key clinical update

Histologic grading to predict outcome has been replaced by serial hCG monitoring.

8) Invasive mole — “deep invasion without true metastasis”

Typically a complete mole that becomes locally invasive.
Key retained feature: still has hydropic villi.
Behavior: villi penetrate deeply into uterine wall → can cause

uterine rupture
life-threatening hemorrhage

Microscopy: atypia with proliferation of both trophoblastic components:

trophoblastic + syncytiotrophoblast components (as described)

Metastases do not occur (important contrast with choriocarcinoma)

Hydropic villi can embolize to distant organs (lungs/brain), but

they do not behave like true metastases
may regress spontaneously

Treatment logic

Because invasion is deeper, complete curettage is difficult
If β-hCG remains elevated, further therapy is needed
Chemotherapy usually cures most cases

9) Gestational choriocarcinoma — “no villi + early vascular spread + very chemo-sensitive”

Origin

Very aggressive malignant tumor
Arises from:

gestational chorionic epithelium (common)
less commonly from totipotential gonadal germ cells (ovary/testis)

Epidemiology

Rare in Western hemisphere: about 1 per 30,000 pregnancies in the US
Much more common in Asian and African countries: up to 1 in 2000 pregnancies

Antecedent pregnancy events (proportions)

~50% arise from complete hydatidiform moles
~25% arise after an abortion
remainder follow an apparently normal pregnancy

Presentation (clinical logic)

Bloody, brownish discharge
Rising β-hCG in blood/urine
No marked uterine enlargement (unlike molar pregnancy)
β-hCG titers are generally much higher than with a mole

Morphology

Gross: hemorrhagic, necrotic uterine masses

necrosis can be so extensive that little viable tumor remains
primary may “self-destruct”; metastases may reveal diagnosis

Invasion pattern: early myometrial and vascular invasion
Microscopy: no chorionic villi

composed of anaplastic:

cytotrophoblasts
syncytiotrophoblasts

Spread pattern (vascular >> lymphatic)

By discovery, widespread vascular spread usually present
Common sites and frequencies given:

Lungs ~50%
Vagina ~30–40%
also brain, liver, kidneys

Lymphatic invasion uncommon

Treatment / prognosis logic

Despite aggression, placental choriocarcinoma is highly chemo-sensitive

Nearly 100% cured, even with distant metastases (e.g., lungs)

Gonadal choriocarcinoma (ovary/testis) responds relatively poorly
Proposed reason for placental tumors doing better:

presence of paternal antigens → maternal immune response may help clear tumor alongside chemotherapy

10) Placental Site Trophoblastic Tumor (PSTT) — “intermediate trophoblast + low hCG + less chemo-sensitive”

Cell of origin: intermediate trophoblast at placental site (overlaps features of cyto- and syncytiotrophoblasts).
Genetics: diploid, often XX.
Timing: typically arises a few months after pregnancy.
Hormone pattern

intermediate trophoblasts do not produce large hCG → hCG only slightly elevated
more typical product: human placental lactogen (hPL)

Clinical course: often indolent

favorable if confined to endomyometrium

Chemo sensitivity: not as sensitive as other trophoblastic tumors

prognosis becomes poor once spread occurs beyond uterus

🟦 Gestational Trophoblastic Disease — Single Comprehensive Comparison Table

Feature	Complete Mole	Partial Mole	Invasive Mole	Gestational Choriocarcinoma	Placental Site Trophoblastic Tumor (PSTT)
Basic nature	Benign trophoblastic proliferation	Benign but abnormal trophoblastic proliferation	Locally invasive form of mole	Highly malignant trophoblastic tumor	Rare trophoblastic tumor
Common origin	Fertilization of empty ovum	Triploid conception	Usually evolves from complete mole	Usually after mole, abortion, or normal pregnancy	Arises from intermediate trophoblast
Genetics	Androgenetic diploid (usually XX)	Triploid (e.g. 69XXY)	Same as complete mole	Gestational (placental) or rarely gonadal	Diploid, often XX
Gross appearance	Uterine cavity expanded by delicate, friable, thin-walled translucent cystic vesicles	Similar but less diffuse	Often destructive, invasive mass	Hemorrhagic, necrotic uterine mass	Nodular infiltrative lesion at placental site
Fetal parts	Rare / absent	Common	Absent	Absent	Absent
Chorionic villi	Present	Present (subset only)	Present (hydropic)	Absent	Absent
Villous edema	Diffuse hydropic swelling	Focal villous edema	Hydropic villi invade myometrium	—	—
Villous vascularity	Poorly vascularized	Partly vascularized	Poor	—	—
Stroma	Loose, myxomatous, edematous	Mild–moderate edema	Similar to complete mole	—	—
Trophoblast proliferation	Diffuse, circumferential	Focal, slight	Marked with atypia	Anaplastic, aggressive	Sheets of intermediate trophoblast
Trophoblast types	Cytotrophoblast + Syncytiotrophoblast	Same (mild)	Cytotrophoblast + Syncytiotrophoblast	Cytotrophoblast + Syncytiotrophoblast	Intermediate trophoblast
Depth of invasion	Confined to endometrium	Confined	Deep myometrial invasion	Early myometrial + vascular invasion	Endomyometrium initially
Metastasis	No	No	No true metastases	Early, widespread vascular spread	Late, uncommon
Embolization	No	No	Hydropic villi may embolize (lung/brain) but regress	True metastases	Rare
Common metastatic sites	—	—	—	Lung (~50%), vagina (30–40%), brain, liver, kidney	—
Uterine size	Enlarged	Mildly enlarged	Variable	Not markedly enlarged	Often normal
β-hCG levels	Very high	Mild–moderate rise	Persistently elevated	Extremely high	Low or mildly elevated
Other hormones	—	—	—	—	hPL increased
Clinical presentation	Vaginal bleeding, enlarged uterus	Vaginal bleeding	Hemorrhage, uterine rupture	Bloody brown discharge, high hCG	Abnormal bleeding months after pregnancy
Histologic grading	Outdated	Outdated	Not used	Not applicable	Not useful
Current monitoring	Serial β-hCG	Serial β-hCG	Serial β-hCG	Serial β-hCG	hCG unreliable
Chemo sensitivity	Not needed	Not needed	Highly sensitive	Extremely chemo-sensitive	Poor chemo response
Primary treatment	Suction curettage	Suction curettage	Chemo if hCG persists	Chemotherapy	Surgery (hysterectomy)
Prognosis	Excellent	Excellent	Excellent with chemo	~100% cure (gestational)	Good if confined, poor if spread
Key exam discriminator	No fetus + diffuse villi	Fetal tissue present	Villi + invasion	No villi + early vascular spread	Low hCG, hPL positive

🧠 Ultra-high-yield exam locks

Villi present → NOT choriocarcinoma
Invasion + villi → invasive mole
No villi + very high hCG + lung mets → choriocarcinoma
Low hCG + hPL + poor chemo response → PSTT
Histologic grading = obsolete → serial hCG is king

If you want, I can:

🔁 convert this into XMind-paste format
🧪 generate spotter-style MCQs
🔍 add immunohistochemistry row (hCG, hPL, Ki-67)

11) Preeclampsia / Eclampsia — mechanism-first, then consequences, then morphology

A) Definitions

Preeclampsia: hypertension + proteinuria + edema developing in 3rd trimester
Occurs in 5–10% of pregnancies
Higher risk emphasized in:

first pregnancies
women older than 35

Eclampsia: preeclampsia + seizures
“Toxemia of pregnancy” is an old term and a misnomer (no toxin identified)
Early recognition/treatment has made fatal eclampsia rare

B) Central pathogenesis (one core defect → many downstream problems)

Core defect: insufficient maternal blood flow to placenta due to inadequate spiral artery remodeling

Normal pregnancy:

trophoblast invasion replaces musculoelastic walls of spiral arteries
arteries dilate into wide vascular sinusoids

Preeclampsia/eclampsia:

remodeling is impaired
musculoelastic walls are retained
channels remain narrow

→ leads to decreased uteroplacental blood flow → placental hypoxia/dysfunction

Angiogenic imbalance (circulating factors)

Increased anti-angiogenic factors: sFlt1 and sEng
Reduced pro-angiogenic factors: e.g., VEGF

→ hypothesized to cause:

endothelial dysfunction
vascular hyperreactivity
end-organ microangiopathy

C) Major consequences (with the logic of “endothelium damaged + hypoperfusion”)

Placental infarction from chronic hypoperfusion
Hypertension mechanism described:

decreased endothelial production of vasodilators prostacyclin and prostaglandin E2
increased production of vasoconstrictor thromboxane A2

Hypercoagulability

driven by endothelial dysfunction
plus release of tissue factor from placenta

End-organ failure

especially kidney and liver
in full-blown eclampsia

D) HELLP syndrome (subset of severe cases)

Occurs in about 10% of patients with severe preeclampsia
Components:

H: elevated liver enzymes
EL: microangiopathic hemolytic anemia
LP: thrombocytopenia due to platelet consumption
may include full-blown DIC

E) Clinical features timeline

Presents insidiously around 24–25 weeks with:

edema
proteinuria
rising blood pressure

If progresses to eclampsia:

renal function impaired
BP rises further
convulsions may occur

Key clinical rule:

prompt therapy early can abort organ changes
abnormalities resolve promptly after delivery / cesarean section

F) Morphology (variable; correlates somewhat with severity)

Placenta

Infarcts

can occur in normal pregnancy, but are much more numerous in severe disease

Retroplacental hemorrhages
Premature maturation of villi with:

villous edema
hypovascularity
increased syncytial epithelial knots

Decidual vessels show:

fibrinoid necrosis
focal lipid-laden macrophages (acute atherosis)

Owner

Untitled

Verification

VULVA

VULVA — COMPLETE CONSOLIDATED TABLE (ZERO-OMISSION)

Category	Condition	Etiology / Cause	Clinical Features	Gross Appearance	Histopathology (Key Exam Lines)	Malignancy Risk / Notes
Inflammatory	Vulvitis	Inflammation of vulva (labia majora + minora)	Pain, pruritus, irritation	Erythema ± edema	Depends on cause	Common, usually benign
	Irritant contact dermatitis	Urine, soaps, detergents, antiseptics, deodorants, alcohol	Intense pruritus → itch–scratch cycle	Red, oozing (“weeping”), crusted papules/plaques	Spongiotic dermatitis,liquid collects between epidermal cells	Trauma from scratching worsens
	Allergic contact dermatitis	Allergy to perfumes, creams, fabric chemicals	Similar to irritant type	Similar appearance	Hypersensitivity reaction	Requires allergen avoidance
Infective	HPV infection	HPV (esp. 6, 11; 16 oncogenic)	Warts(condyloma acuminata) ± VIN	Papillary / flat lesions	Koilocytosis	Oncogenic risk with high-risk types
	HSV-1 / HSV-2	Viral	Painful vesicles → ulcers	Vesicles, erosions	Multinucleated giant cells (TZANK cells with cowdry inclusions bodies,+ in VZV too)	Recurrent
	Neisseria gonorrhoeae	Bacterial STI	Purulent discharge	Inflamed gland openings	Neutrophilic inflammation	Can involve Bartholin glands
	Treponema pallidum	Syphilis	Painless chancre	Ulcer	Plasma cells, obliterative endarteritis	Primary syphilis
	Candida species	Yeast (non-STI)	Pruritus, soreness	Erythema ± discharge	Pseudohyphae	Common
Complication	Bartholin duct obstruction	Inflammation/infection	Painful swelling	Cyst ± abscess	Cystic dilation	Surgical relevance
Non-neoplastic epithelial disorders	Lichen sclerosus	Autoimmune (T-cell mediated)	Pruritus, dyspareunia, introital narrowing	Smooth white plaques (leukoplakia)	Thin epidermis, loss of rete pegs, dense homogenized subepithelial fibrosis, band-like lymphocytes	1–5 % → HPV-negative vulvar SCC
	Lichen simplex chronicus	Chronic irritation / scratching	Persistent pruritus	Thickened white plaques	Acanthosis, hyperkeratosis, ↑ basal mitoses, no atypia,Thickened epidermis	Not premalignant; reactive
Benign tumor-like lesions	Condylomata lata	Secondary syphilis	Moist lesions	Flat plaques	Plasma cell infiltrate	Infectious marker
	Condylomata acuminata	HPV 6 & 11 (>90 %)	Usually asymptomatic	Papillary or flat warts	Acanthosis + hyperkeratosis + koilocytosis	Not precancerous
Malignant	Vulvar carcinoma (overall)	Multifactorial	Ulcer, mass, pruritus	Leukoplakia → ulcer/exophytic	Invasive SCC	~3 % GYN cancers
	HPV-positive SCC pathway	HPV-16 ± smoking	Middle-aged	Warty, multifocal	Basaloid cells, poor differentiation, high N:C ratio, minimal keratinization	Slow progression
	HPV-negative SCC pathway	Lichen sclerosus → dVIN	Elderly	Unifocal, keratinizing	Well-differentiated, keratin pearls, prominent keratinization	More aggressive
Special malignancy	Extramammary Paget disease	Epidermal progenitor cells	Eczema-like pruritic plaque	Red, scaly, crusted	Large pale Paget cells, mucin-positive (PAS)	Usually no underlying carcinoma
Spread & prognosis	Vulvar SCC spread	—	—	—	Depth-dependent invasion	Inguinal nodes first
	Survival	—	—	—	—	70–93 % (node-negative) vs 25–41 % (node-positive)

Exam Lock 🔒 (One-Look Recall)

White thin vulva + fibrosis → Lichen sclerosus → HPV-negative SCC
Thickened epidermis + no atypia → Lichen simplex chronicus
Koilocytosis = HPV
Keratin pearls = HPV-negative vulvar SCC
Red scaly eczema-like vulva = Think Paget

NOTE-

🔹 Vulvitis

Vulvitis means inflammation of the vulva — the outer female genital area, including the labia majora (skin with hair) and labia minora (mucosa).

It’s common, usually painful and itchy, but not usually dangerous.

⚙️ Causes

Irritant or Allergic Contact Dermatitis

Irritant form → triggered by urine, soaps, detergents, antiseptics, deodorants, or alcohol.

It looks red and oozing (“weeping”) with crusting papules or plaques.

Allergic form → same look, but due to allergy to perfumes, additives in creams or lotions, fabric chemicals, etc.
Scratching (→ trauma) makes it worse and causes a “itch-scratch” cycle (pruritus → scratch → more inflammation).

Infections

Often sexually transmitted (STIs).

Common organisms:

Human papillomavirus (HPV) → condyloma acuminatum, vulvar intraepithelial neoplasia (VIN), and some squamous carcinomas.
Herpes simplex virus (HSV-1 / HSV-2) → genital herpes.
Neisseria gonorrhoeae → pus-forming infection of vulvovaginal glands.
Treponema pallidum → chancre of syphilis (primary lesion).
Candida species → yeast vulvitis (not sexually transmitted).

⚠️ Complication

Bartholin gland duct obstruction → painful cyst (Bartholin cyst) ± abscess formation.

🔹 Non-Neoplastic Epithelial Disorders

Lichen Sclerosus

Thinning of the epidermis + loss of rete pegs + dense homogenized fibrosis beneath the epithelium + band-like lymphocytic infiltrate.
Appears as smooth, white patches (“leukoplakia”) that may merge together.
Common in postmenopausal women and prepubertal girls.
Probably autoimmune (T-cell infiltrate + association with other autoimmune diseases).
Clinical effects: labial atrophy, narrowed vaginal opening → dyspareunia.
Malignancy risk: 1 – 5 % progress to HPV-negative squamous cell carcinoma of vulva.

Lichen Simplex Chronicus

Chronic irritation → thickened epidermis (acanthosis + hyperkeratosis) with increased mitoses in basal layers.
No cellular atypia.
Usually related to persistent pruritus or underlying dermatitis.
Produces white plaques (also called leukoplakia).
Cancer risk: not inherent — but often seen at edges of vulvar carcinomas → may reflect reactive change.

Figure 19-1 — Non-neoplastic vulvar epithelial disorders (A) Lichen sclerosus: thin epidermis + fibrosis + chronic inflammation. (B) Lichen simplex chronicus: thick epidermis + hyperkeratosis.

🔹 Tumors of the Vulva

Condylomas (Genital Warts)

Any warty vulvar lesion = condyloma.
Two types:

Condylomata lata – flat lesions of secondary syphilis.

Condylomata acuminata – HPV-related (> 90 % due to types 6 & 11 – “low-risk” HPV).\

Appearance → papillary or flat warty growths (red-pink to brown), often multiple, few mm to cm.
Histology: acanthosis + hyperkeratosis + koilocytosis (perinuclear vacuoles, wrinkled nuclei).
Not precancerous but signal HPV exposure → check for other HPV lesions in vagina/cervix.

Fig 19-2 A–B — Condyloma acuminatum: gross multiple warts & microscopic koilocytosis.

Carcinoma of the Vulva

~ 3 % of female genital tract cancers; mostly women > 60 yrs.
90 % = Squamous cell carcinoma.
Two distinct pathways:

HPV-related (16) — in middle-aged women ± smokers; precedes VIN (vulvar intraepithelial neoplasia).

Progression slow → years; not inevitable.

HPV-negative (lichen sclerosus related) — in elderly women with differentiated VIN (dVIN) precursor.

dVIN = atypia in basal layer + abnormal keratinization.

Histologic Feature	HPV-Positive SCC	HPV-Negative SCC
Degree of differentiation	Poorly differentiated	Well differentiated
Tumor cell type	Basaloid squamous cells	Mature squamous cells
Nuclear features	High nuclear-to-cytoplasm ratio, hyperchromatic nuclei	Relatively uniform nuclei
Keratinization	Minimal or absent	Prominent
Keratin pearls	Absent	Present
Intercellular bridges	Poorly formed or absent	Well formed
Growth pattern	Warty / papillary / exophytic	Solid nests and cords
Surface architecture	Papillomatous	Ulcerated or infiltrative
Mitoses	Numerous	Fewer
Koilocytosis	May be present	Absent
Stromal invasion	Present	Present

Morphology:

Lesions start as leukoplakia (± pigmented) → ulcerated or exophytic tumors.
HPV-positive type → multifocal, warty, poorly differentiated.

HPV-negative type → unifocal, well differentiated, keratinizing.

Spread → local invasion then inguinal lymph nodes; depth of invasion predicts risk.

Prognosis: 5-yr survival ≈ 70–93 % (no node spread) vs 25–41 % (with node metastasis).

Extramammary Paget Disease (Vulva)

Intra-epidermal proliferation of malignant epithelial cells (Paget cells).
Unlike Paget of breast → usually no underlying carcinoma.
Origin → epidermal progenitor cells.
Clinical: red, scaly, crusted plaque mimicking eczema or dermatitis.

Histology: large pale cells with finely granular cytoplasm + occasional vacuoles in epidermis; mucin positive on PAS stain.
May persist for years; if associated appendage carcinoma → invasive + metastatic potential.

Fig 19-3 — Paget disease of vulva: Paget cells in epidermis with chronic inflammation beneath.

VAGINA

🦠 Vaginitis

Common, transient inflammation → leukorrhea (vaginal discharge)
Predisposing factors: diabetes, antibiotic therapy, immunodeficiency, pregnancy, recent abortion
Causative organisms:

Candida albicans → curdy white discharge

• Normal flora in ≈ 5 % of women

• Symptomatic disease = needs predisposing factor / superinfection

Trichomonas vaginalis → sexually transmitted

• Watery, copious gray-green discharge

• Motile parasites on microscopy

• Found in ≈ 10 % of asymptomatic women

Primary Neisseria gonorrhoeae infection in vagina = rare in adults

⚠️ Malignant Neoplasms

1️⃣ Squamous Cell Carcinoma

Very rare
Usually > 60 y
Risk factors = similar to cervical carcinoma
Precursor: VAIN (vaginal intraepithelial neoplasia) — HPV-related
HPV DNA detectable in > 50 % cases

2️⃣ Clear Cell Adenocarcinoma

Seen in young women exposed in utero to DES (diethylstilbestrol)
Incidence < 1 / 1000 (but ≈ 40 × background)
Precursor = Vaginal adenosis (red granular mucosa with mucus-secreting/ciliated cells)

Microscopic (histologic) description

Tumor has cystic, papillary, tubular / glandular and solid architectural patterns with focal necrosis
Cells have distinct cell membranes, are large with moderate to abundant clear cytoplasm, occasionally may be oxyphilic
Cells are usually cuboidal and sometimes hobnail type with nuclei protruding into the lumen
Nuclei are round to irregular, hyperchromatic with conspicuous nucleoli

3️⃣ Sarcoma Botryoides (Embryonal Rhabdomyosarcoma)

Soft polypoid “grape-like” mass (protruding lesion)
Occurs in infants and children < 5 years (rare in young adults)

The surface epithelium may show pseudoepitheliomatous hyperplasia mimicking carcinoma. There is strong immunoreactivity for myogenic antigens, including myogenin, muscle-specific actin, and desmin

VAGINA — INFLAMMATORY & MALIGNANT CONDITIONS (COMPLETE TABLE)

Category	Condition	Typical Age / Group	Etiology / Risk Factors	Discharge / Gross Features	Key Microscopy / Histology	Special Exam Notes
Inflammatory (Vaginitis)	General Vaginitis	Reproductive age	Diabetes, antibiotics, immunodeficiency, pregnancy, recent abortion	Leukorrhea (vaginal discharge)	Inflammatory changes	Common, transient
	Candida albicans	Any age	Normal flora (~5%) → symptomatic only with predisposing factor / superinfection	Curdy white discharge	Budding yeast, pseudohyphae	NOT STD
	Trichomonas vaginalis	Sexually active women	Sexually transmitted	Watery, copious gray-green discharge	Motile parasites on microscopy	~10% asymptomatic carriers
	Neisseria gonorrhoeae (primary vaginal infection)	Adults	STD	—	—	Rare in adults
Malignant Neoplasm	Squamous Cell Carcinoma	> 60 years	Same as cervical cancer (HPV, smoking, etc.)	Vaginal mass / ulcer	Invasive squamous carcinoma	Very rare
			Precursor: VAIN	—	—	HPV DNA detectable in >50%
Malignant Neoplasm	Clear Cell Adenocarcinoma	Young women	In-utero DES exposure	Vaginal mass	See below	Incidence <1/1000, 40× background
			Precursor: Vaginal adenosis	Red granular mucosa, mucus-secreting / ciliated cells	—	Classic USMLE / PGIM favorite
	Clear Cell Adenocarcinoma — Histology	—	—	—	Architectural patterns: cystic, papillary, tubular/glandular, solid + focal necrosis	Must list patterns
					Cells: large, cuboidal, clear cytoplasm (± oxyphilic)
					Hobnail cells (nuclei protruding into lumen)	🔑 buzzword
					Nuclei: round–irregular, hyperchromatic, prominent nucleoli
Malignant Neoplasm	Sarcoma Botryoides (Embryonal rhabdomyosarcoma)	Infants & children <5 y (rare in young adults)	Mesenchymal tumor	Soft, polypoid, grape-like protruding mass	Primitive small cells → stellate → spindle rhabdomyoblasts	Appearance is classic
					Loose myxomatous stroma
					Cambium layer (hypercellular subepithelial zone)	🔑 exam line
					Pseudoepitheliomatous hyperplasia of surface epithelium	Mimics carcinoma
					Immunoreactivity: myogenin, muscle-specific actin, desmin	Confirms myogenic origin

🔑 Ultra-High-Yield Exam Locks

DES → Clear cell adenocarcinoma → Vaginal adenosis
HPV → VAIN → Vaginal SCC
Grape-like vaginal mass in child → Sarcoma botryoides
Hobnail cells + clear cytoplasm = Clear cell adenocarcinoma
Candida needs a trigger; Trichomonas is an STD

CERVIX

CERVIX — Inflammation, Neoplasia & Benign Lesions (Complete Table)

Domain	Entity / Lesion	Key Points	Pathogenesis / Morphology	Natural History / Risk	Diagnosis / Screening	Management / Notes
Inflammatory	Cervicitis	• Very common • Presents with leukorrhea	• Infection of cervical epithelium	• Usually acute • Can persist if untreated	• NAAT for pathogen identification	• Empiric antibiotics active against Chlamydia + Gonococcus
	Infectious agents	• Chlamydia trachomatis (~40% STI clinic cases) • Ureaplasma urealyticum • Trichomonas vaginalis • Neisseria gonorrhoeae • HSV-2 • HPV	• Pathogen-specific epithelial infection	• HSV → risk of neonatal systemic infection if transmitted at birth	• NAAT	• Treat patient + partner(s)
Pre-neoplastic (Pathogenesis)	Cervical neoplasia – general	• Most tumors are epithelial • HPV-related	• Occurs at transformation zone (columnar → squamous metaplasia after puberty)	• Persistent high-risk 16,18HPV = key driver	• Cytology + HPV DNA testing	• Prevention via screening & HPV vaccination
	High-risk HPV	• HPV-16, HPV-18 ≫ others	• Infect immature squamous cells	• Persistent infection → SIL → carcinoma	• HPV DNA testing (≥30 y)	• Oncoproteins drive malignancy
	Oncoproteins	• E6 → inhibits p53 • E7 → inhibits RB	• Loss of cell-cycle control	• Genomic instability	• Indirect via cytology/HPV testing	• Central molecular mechanism
	Other risk factors	• Early first intercourse • Multiple sexual partners • Male partner with many partners • Persistent HPV	• ↑ HPV exposure + persistence	• ↑ lifetime cancer risk	—	• Epidemiologic risk clustering
Pre-invasive lesion	Squamous Intraepithelial Lesion (SIL)	• HPV-related pre-cancerous lesion	• Dysplasia of squamous epithelium	• Long latent period	• Pap smear	• Managed based on grade
	Age peaks	• SIL ~30 y • Invasive cancer ~45 y	—	• ~10–15 y progression window	—	• Key exam timeline
	LSIL (CIN I)	• Productive HPV infection	• Mild dysplasia • Preserved maturation	• 60% regress • 30% persist • 10% → HSIL	• Pap smear	• NOT premalignant • Observe
	HSIL (CIN II–III)	• True precancerous lesion	• ↑ proliferation • Loss of maturation	• 30% regress • 60% persist • 10% → carcinoma (~10 y)	• Pap + biopsy	• Excise / cone biopsy
Screening	Cervical screening	• Early detection of SIL	—	↓ cancer incidence	• Pap smear • Pap + HPV DNA ≥30 y	• Prevents invasive disease
Malignant	Invasive carcinoma – overall	• All are HPV-related	• Stromal invasion	• Metastatic risk depends on depth	• Biopsy + staging	• Treatment stage-dependent
	Histologic types (%)	• Squamous ~75% • Adeno / adenosquamous ~20% • Small-cell neuroendocrine <5%	• Squamous: keratinization common	• Neuroendocrine → aggressive	• Histopathology	• Cell type affects prognosis
	Adenocarcinoma trend	• Incidence rising	• Endocervical origin	• Often missed by Pap	• HPV DNA + biopsy	• Screening challenge
	Depth vs metastasis	• <3 mm invasion → <1% LN • >3 mm invasion → >10% LN	• Depth reflects stromal breach	• Key staging determinant	• Histologic measurement	• Exam-favorite statistic
	Morphology	• Tongues/nests of malignant squamous cells	• Desmoplastic stroma • ± keratin pearls	—	• Histology	• Classic appearance
	Clinical features	• Abnormal vaginal bleeding • Leukorrhea • Dyspareunia • Dysuria	• Local invasion	• Often late presentation	• Clinical + biopsy	• Red-flag symptoms
	Treatment	• Hysterectomy + LN dissection	—	—	—	• Microinvasive → cone biopsy • ± RT / CT
	Prognosis	• Depends on stage	• Neuroendocrine worst	—	—	• Stage is king
Benign	Endocervical polyp	• Common benign lesion	• Polypoid endocervical mucosa	• No malignant potential	• Speculum exam	• Reassurance / excision if symptomatic
	Gross features	• Smooth • Glistening • ± mucin-filled cysts	—	—	—	—
	Microscopy	• Epithelium: mucus-secreting columnar cells • Stroma: edematous + chronic inflammation • ± squamous metaplasia	—	—	• Histology	• May cause bleeding

Cervical Squamous Neoplasia — Complete Histological Continuum (One Table)

Feature	LSIL (CIN I)	HSIL (CIN II)	HSIL (CIN III / CIS)	Invasive Squamous Cell Carcinoma
Level of pathology	Intraepithelial	Intraepithelial	Intraepithelial (pre-invasive)	Stromal invasion present
Site	Transformation zone	Transformation zone	Transformation zone	Transformation zone
Depth of epithelial involvement	Lower ⅓ only	Lower ⅔ (to middle third)	Almost full thickness	Beyond basement membrane
Basement membrane	Intact	Intact	Intact	Breached
Epithelial maturation	Preserved	Partial loss	Almost complete loss	Lost (invasive growth)
Cellular differentiation	Mostly normal	Moderately abnormal	Markedly abnormal	Variable (poor → well differentiated)
Nuclear size & shape	Mild enlargement	Moderate pleomorphism	Severe pleomorphism	Marked pleomorphism
Chromatin pattern	Slightly irregular	Heterogeneous	Coarse, irregular	Coarse, hyperchromatic
Mitoses	Rare, basal only	↑ mitoses above basal layer (some atypical)	Numerous, abnormal at all levels	Numerous, atypical
Koilocytosis (HPV effect)	Prominent (superficial layers)	Occasional	Absent	Absent
Architectural order	Preserved layering	Partial disorganization	Severe disorganization	Tongues & nests invading stroma
Stromal response	None	None	None	Desmoplastic reaction
Keratin pearl formation	Absent	Absent	Absent	Present in well-differentiated tumors
Special variants	—	—	—	Rare neuroendocrine (small-cell–like)
Gross appearance	Not visible	Not visible	Not visible	Microscopic → exophytic / barrel cervix
Clinical palpation	Normal	Normal	Normal	Barrel cervix, fixed uterus
Parametrial involvement	No	No	No	Possible (uterine fixation)
Lymphovascular invasion	Absent	Absent	Absent	May be present
Risk of metastasis	None	None	None	<1% (<3 mm) → >10% (>3 mm)

Progression Logic (Exam Gold Line)

Cervical cancer progresses from lower-third dysplasia with koilocytosis → full-thickness loss of maturation → stromal invasion with desmoplasia, architectural destruction, and metastatic potential once depth exceeds 3 mm.

Ultra-Short Memory Lock

Koilocytes → gone
Maturation → lost
Basement membrane → broken
Stroma reacts → desmoplasia
Depth > 3 mm → nodes matter

🩸 Cervicitis

Very common → leukorrhea
Infectious agents:

Chlamydia trachomatis (~ 40 % STI clinic cases)
Ureaplasma urealyticum, T. vaginalis, N. gonorrhoeae, HSV-2, HPV

Herpes infection → neonatal systemic infection (if transmitted at birth)
Empiric Rx = antibiotics active vs chlamydia + gonococcus
NAAT for pathogen ID

🧬 Neoplasia of the Cervix — Pathogenesis

Most tumors = epithelial, HPV-related
Transformation zone: site where columnar → squamous metaplasia (post-puberty)
High-risk HPV (16, 18 ≫) infects immature squamous cells
Oncoproteins: E6 → inhibits p53 | E7 → inhibits RB
Other risk factors:

Early first intercourse
Multiple sexual partners
Male partner with many previous partners
Persistent high-risk HPV infection

Fig 19-4: Transformation zone illustration

🧫 Squamous Intraepithelial Lesion (SIL)

Pre-cancerous HPV-related lesion
Peaks: SIL ~30 y | Invasive Ca ~45 y
Classification (two-tier):

LSIL (CIN I) → productive HPV infection | 60 % regress | 30 % persist | 10 % progress to HSIL
HSIL (CIN II–III) → ↑ proliferation, loss of maturation | 30 % regress | 60 % persist | 10 % progress to carcinoma within ≈ 10 y

LSIL = not premalignant (→ observe)

HSIL = precancerous (→ excise / cone biopsy)

Screening: Pap smear (+ HPV DNA test ≥ 30 y)
Fig 19-6: Spectrum of SIL
Fig 19-7: Pap cytology appearance
Table 19-1: Natural history of SILs

🧠 Invasive Carcinoma of the Cervix

Types (%): Squamous ~75 | Adeno/Adenosquamous ~20 | Small-cell Neuroendocrine <5
All HPV-related
Adenocarcinoma fraction rising (less detectable by Pap)
Peak age: ~45 y (≈ 10–15 y after SIL)
Depth vs metastatic risk: < 3 mm → < 1 % nodes | > 3 mm → > 10 % nodes
Morphology: Tongues/nests of squamous cells + desmoplastic stroma ± keratin pearls
Fig 19-8: Exophytic invasive carcinoma
Clinical features: abnormal vaginal bleeding, leukorrhea, dyspareunia, dysuria
Treatment: Hysterectomy + LN dissection | Microinvasive → cone biopsy | Adjunct RT/CT as needed
Prognosis: depends on stage (+ cell type for neuroendocrine)

🩹 Endocervical Polyp

Benign polypoid mass of endocervical mucosa
Smooth, glistening surface ± mucin-filled cysts
Epithelium = mucus-secreting columnar cells
Stroma = edematous + chronic inflammation ± squamous metaplasia
May bleed but no malignant potential

UTERUS

🧫 Endometritis

Acute (neutrophils) vs chronic (lymphocytes + plasma cells).
Causes: N. gonorrhoeae, C. trachomatis (PID); tuberculous endometritis (granulomatous) esp. in TB-endemic origin or immunocompromised; retained products/IUD → ascending infection.
Clinical: fever, abdominal pain, menstrual abnormalities; ↑ risk of infertility/ectopic pregnancy.

💠 Adenomyosis

Endometrial tissue in myometrium → reactive myometrial hypertrophy → enlarged, globular uterus.
Symptoms: menorrhagia, dysmenorrhea, pelvic pain (often pre-menses); may coexist with endometriosis.

🌿 Endometriosis

Endometrial glands + stroma outside uterus; up to ~10% reproductive-age; ~50% in infertility.
Sites: pelvis (ovaries, pouch of Douglas, ligaments, tubes, rectovaginal septum) ± distant (LN, lung, heart, skeletal muscle, bone).
Origins (4): regurgitation (favored), benign metastases, metaplastic, extrauterine stem/progenitor cells.
Lesions are functioning endometrium → cyclic bleeding; ovarian cysts → “chocolate cysts.”
Dx requires both glands and stroma ectopically.

🩸 ABNORMAL UTERINE BLEEDING

🔹 Clinical Patterns

Menorrhagia – prolonged / profuse period bleeding
Metrorrhagia – irregular bleeding between periods
Post-menopausal bleeding – requires exclusion of malignancy

🔹 Major Causes

Dysfunctional uterine bleeding (DUB) – no organic lesion
Endometrial polyp • Leiomyoma • Endometrial hyperplasia / carcinoma

🔹 Mechanisms of DUB

Anovulatory cycles (MC cause) → hormonal imbalance

At menarche / perimenopause (↑ axis fluctuations)
Endocrine disorders (thyroid, adrenal, pituitary tumor)
Ovarian lesions (e.g. PCOS, granulosa cell tumor)
Metabolic states (obesity, malnutrition, chronic illness)

Inadequate luteal phase → low progesterone from corpus luteum

Table 19-2 — Causes of Abnormal Uterine Bleeding by Age Group • Prepuberty – precocious puberty (hypothalamic/pituitary/ovarian) • Adolescence – anovulatory cycles • Reproductive age – pregnancy complications (abortion, trophoblastic disease, ectopic); proliferations (leiomyoma, adenomyosis, polyps, hyperplasia, carcinoma); anovulation / luteal defect • Perimenopause – anovulation ± irregular shedding ± proliferations • Post-menopause – proliferations or endometrial atrophy

🌱 ENDOMETRIAL HYPERPLASIA

ENDOMETRIAL HYPERPLASIA — COMPLETE INTEGRATED TABLE (ZERO-OMISSION)

Domain	Hyperplasia WITHOUT Atypia	Atypical Hyperplasia / EIN
Core definition	Excess unopposed estrogen → exaggerated endometrial proliferation without cytologic atypia	Clonal neoplastic proliferation with cytologic atypia → precursor to Type I endometrioid carcinoma
Primary hormonal driver	Persistent estrogen without progesterone	Same hormonal driver PLUS genetic alterations
Common causes of estrogen excess	• Obesity (↑ aromatase in fat) • Anovulation (perimenopause, PCOS) • Exogenous estrogen therapy (no progestin) • Estrogen-producing ovarian tumors (granulosa-theca) • Tamoxifen (partial agonist)	Same causes; often long-standing / severe exposure
Pathogenesis – hormonal	Unopposed estrogen → continuous proliferation → glandular crowding	Same → selection of abnormal clone
Pathogenesis – genetic	Usually no driver mutation	PTEN loss (~50–55%) → PI3K/AKT activation → survival & proliferation
Key molecular pathway	Estrogen-driven hyperplasia	PTEN → PIK3CA → KRAS → ARID1A → MMR/MSI
WHO 2014 / 2020 category	Hyperplasia without atypia	Atypical hyperplasia / EIN
EIN diagnostic criteria	❌ Not applicable	✅ All required:• Gland > stroma (G:S >1)• Cytology different from background• Size >1 mm• Exclude mimics (polyps, repair, secretory)• No invasion
Architecture	Mild–moderate gland crowding Cystic dilation (“Swiss cheese”)	Marked glandular crowding,Complex branching, irregular outlines
Cytology	Normal columnar cells No nuclear atypia	Enlarged round nuclei, loss of polarity, coarse chromatin, nucleoli
Stroma	Abundant, intervening	Scant, compressed
Mitotic activity	Increased but orderly	Increased with abnormal forms
PTEN (IHC)	Retained	Often lost (useful diagnostic marker)
Other IHC markers	ER+, PR+, PAX8+	ER+, PR+, PAX8+
MMR status	Usually intact	May show MMR loss → consider Lynch syndrome
ARID1A	Usually intact	Mutated in subset (shared with carcinoma)
Clinical presentation	Abnormal uterine bleeding (AUB)Infertility work-up	Same; often detected on biopsy
Carcinoma coexistence	<1–3%	25–40% already have carcinoma
Progression risk	~1–3%	20–50% progression risk
Natural behavior	Often regresses with progesterone	True premalignant lesion
Management – fertility desired	Progestin therapy (oral / cyclic / LNG-IUS) + treat cause	High-dose progestin (LNG-IUS) with strict biopsy surveillance
Management – completed parity / postmenopausal	Progestin ± hysterectomy if persistent	Definitive total hysterectomy (± BSO by age)
Follow-up	Repeat biopsy every 3–6 months	Mandatory close follow-up if conservative
Relationship to carcinoma	Pre-estrogenic field change	Direct precursor to Type I endometrioid carcinoma
Stepwise pathway	Estrogen excess → hyperplasia	Estrogen → hyperplasia → EIN → carcinoma
Classic figure correlation (Fig 19-11)	A: disordered anovulatory endometrium B: hyperplasia without atypia	C: hyperplasia with atypia

One-line EXAM LOCK 🔒

Atypical hyperplasia (EIN) = clonal PTEN-driven premalignant lesion with 20–50% carcinoma risk → treat definitively unless fertility required.

🧬 ENDOMETRIAL CARCINOMA

Endometrial Carcinoma — Complete Logic-Based Comparison Table (Zero Omission)

Domain	Endometrioid Carcinoma (Type I)	Serous Carcinoma (Type II)
Overall frequency	~80% of endometrial carcinomas	~15% of endometrial carcinomas
Geographic relevance	Most common type in US & Western countries	Less common but clinically critical
Typical age group	Perimenopausal women (usually 55–65 y)	Older postmenopausal women
Occurrence before 40 y	Uncommon	Uncommon
Estrogen association	YES – strongly estrogen-dependent	NO – estrogen independent
Hormonal environment	Estrogen excess	No estrogen excess
Background endometrium	Endometrial hyperplasia	Endometrial atrophy
Pathogenetic pathway	Hyperplasia → carcinoma	Atrophy → carcinoma
Histologic resemblance	Resembles normal endometrial glands	Markedly atypical epithelium
Reason for name	“Endometrioid” due to glandular similarity	Named for serous-type morphology
Major risk factors	Obesity, diabetes, hypertension, infertility, unopposed estrogen	Not linked to classical estrogenic risk factors
Mechanism behind risk factors	All → ↑ estrogenic stimulation → hyperplasia	Not hormone driven
Exogenous estrogen risk	Prolonged estrogen replacement therapy ↑ risk	No association
Ovarian tumor association	Estrogen-secreting ovarian tumors ↑ risk	No association
Key early molecular events	PTEN mutation, DNA mismatch repair (MMR) gene mutations	TP53 mutation (early and universal)
Late molecular events	TP53 mutation (uncommon, late)	—
Inherited syndromes	Cowden syndrome (PTEN), Lynch syndrome (MMR)	Not characteristically associated
Precursor lesion	Endometrial hyperplasia (esp. atypical)	Serous Endometrial Intraepithelial Carcinoma (SEIC)
Role of TP53	Late, relatively uncommon	Early, near-universal
Gross growth pattern	Exophytic or infiltrative	Often subtle, papillary
Microscopic architecture	Glandular patterns resembling normal endometrium	Small tufts, papillae, may form glands
Cytologic atypia	Mild–moderate (grade-dependent)	Marked cytologic atypia
Histologic variants	Mucinous, tubal (ciliated), squamous differentiation	Limited differentiation patterns
Myometrial invasion	Common	Common and often deep
Lymphovascular invasion	May occur	Frequent
Regional lymph node spread	Possible	Common
Tumor grading	Grade 1–3 (based on differentiation)	Always high-grade by definition
Immunohistochemistry	Variable p53 staining	Diffuse, strong p53 positivity
p53 staining mechanism	—	Mutant p53 accumulates → detectable
Biologic behavior	Relatively indolent	Highly aggressive
Typical clinical presentation	Irregular or postmenopausal bleeding	Same presentation
Uterine changes with progression	Uterine enlargement	Uterine enlargement
Local tissue infiltration	Occurs with progression	Early and extensive
Fixation to surrounding structures	Late	Common
Metastatic tendency	Slow if untreated	Early and rapid
Stage at presentation	Often early stage	Often high stage
5-year survival (early stage)	≈ 90%	Lower even when treated
Effect of advancing stage	Survival drops sharply	Poor prognosis overall
Dependence on operative staging	Important	Critical for prognosis
Overall prognosis	Generally favorable if early	Generally poor

One-Line Exam Lock (optional memory anchor)

Endometrioid = estrogen + hyperplasia + PTEN/MMR + graded
Serous = atrophy + TP53 + always high-grade + aggressive

EXAM-LOCK SUMMARY (ONE-GLANCE)

Type I = Estrogen + Hyperplasia + PTEN + Better prognosis
Type II = p53 + Atrophic endometrium + Aggressive
Serous carcinoma behaves like ovarian serous cancer
Carcinosarcoma = carcinoma with sarcomatous disguise
Depth of myometrial invasion = strongest prognostic factor

🌿 ENDOMETRIAL POLYPS

Sessile 0.5–3 cm, may project into cavity.
Endometrium resembles basalis layer; thick-walled arteries.
Glands: normal → cystic dilation.
Stroma: monoclonal cells with 6p21 rearrangement (neoplastic component).
Age: perimenopausal common.
Clinical: abnormal bleeding; benign.

💪 LEIOMYOMA ( = Uterine Fibroid )

Most common benign tumor in women (30 – 50 %); ↑ in Black women.
Origin: myometrial smooth muscle.
Genetics: recurrent chr 6 / 12 rearrangements + MED12 mutation (~ 70 %).
Hormonal dependence: ↑ with estrogen / OCP; ↓ post-menopause.
Morphology (Fig 19-13): sharply circumscribed gray-white whorled masses; single or multiple (intramural, submucosal, subserosal).
Clinical: menorrhagia, pelvic mass effect, infertility (if cavity distortion); no malignant potential.

⚠️ LEIOMYOSARCOMA

Malignant smooth-muscle tumor (arises de novo).
Gross = soft, bulky, hemorrhagic/necrotic.
Micro = spindle cell atypia + high mitotic index.
Behavior: frequent recurrence + lung/brain metastases → poor prognosis.

Absolutely — picking up where we left off and restarting the remaining sections with MICRO-AUDITS, still point-form and Breast excluded.

🧬 FALLOPIAN TUBES

Serous Tubal Intraepithelial Carcinoma (STIC)

Earliest precursor for many “ovarian” high-grade serous carcinomas.
Genetics: TP53 mutations in >90%.
Epidemiology/setting: often found in prophylactic salpingo-oophorectomy specimens from BRCA1/BRCA2 carriers.
Site: fimbrial end; plausible seeding to ovarian/peritoneal surfaces.

Endometrial Polyps vs Leiomyoma vs Leiomyosarcoma — Complete Comparison Table

Feature	Endometrial Polyps	Leiomyoma (Fibroid)	Leiomyosarcoma
Nature	Benign endometrial lesion	Benign smooth muscle tumor	Malignant smooth muscle tumor
Cell of Origin	Endometrial stromal cells (neoplastic component)	Smooth muscle cells of myometrium	Mesenchymal cells of myometrium
Neoplastic Component	Stroma is monoclonal	Smooth muscle cells	Malignant smooth muscle cells
Genetics / Molecular	Rearrangement of chromosomal region 6p21	Recurrent chromosomal rearrangements of chromosomes 6 & 12; MED12 mutations (up to 70%)	No precursor lesion; arises de novo
Hormonal Influence	Not emphasized	Estrogen-dependent growth; stimulated by estrogens ± OCPs; shrink postmenopause	Not estrogen dependent
Typical Age Group	Any age, most common around menopause	Reproductive age	Postmenopausal
Incidence / Frequency	Common	Most common benign tumor in females (30–50%)	Rare
Ethnic Predilection	Not specified	More common in black women	Not specified
Number of Lesions	Usually single	Often multiple	Almost always solitary
Size	0.5 – 3 cm	Variable: small nodules → very large masses	Variable, often large
Gross Appearance	Sessile; larger polyps may project into uterine cavity	Firm, gray-white, sharply circumscribed, whorled cut surface	Soft, hemorrhagic, necrotic
Location	From endometrial mucosa, may protrude into cavity	Intramural, submucosal, subserosal	Within myometrium
Special Gross Variants	—	Parasitic leiomyomas (pedunculated, attached to surrounding organs with new blood supply)	—
Histologic Glands	Some normal; more often cystically dilated	—	—
Histology (Cells)	Endometrium resembling basalis; small muscular arteries	Bundles of smooth muscle resembling normal myometrium	Variable: well-differentiated → wildly anaplastic
Degenerative Changes	—	Fibrosis, calcification, degenerative softening	Hemorrhage & necrosis
Clinical Presentation	Abnormal uterine bleeding	Often asymptomatic; menorrhagia ± metrorrhagia	Rapid growth, postmenopausal mass, systemic effects
Discovery	Symptomatic bleeding or incidental	Often incidental on pelvic exam	Symptomatic
Malignant Potential	Benign	Rarely, if ever, transform; multiplicity ≠ ↑ risk	Frankly malignant
Recurrence	—	—	Common after surgery
Metastasis	—	—	Common, especially to lungs
Prognosis	Excellent	Excellent	Poor
5-Year Survival	—	—	~40%
Special Diagnostic Category	—	—	STUMP (Smooth muscle tumor of uncertain malignant potential)
Key Diagnostic Criteria (Histology)	Monoclonal stroma	Benign smooth muscle	Triad required: tumor necrosis + cytologic atypia + mitotic activity
Diagnostic Pitfall	—	High mitotic activity may occur in benign tumors (young women)	Mitotic count alone is insufficient

Ultra-High-Yield Exam Locks 🔒

Endometrial polyp = monoclonal stroma + cystically dilated glands + AUB
Leiomyoma = estrogen-dependent, whorled, multiple, benign
Leiomyosarcoma = de novo, solitary, postmenopausal, necrosis + atypia + mitoses
Fibroids ≠ sarcoma risk
Rapid growth postmenopause → think sarcoma

Fallopian Tube Disorders — Complete Integrated Table (Zero Omission)

Domain	Aspect	Details (Logic + Exam-Safe)
Epidemiology	Most common disorder	Inflammation (salpingitis)
	Clinical context	Almost always part of Pelvic Inflammatory Disease (PID)
Less common disorders	Other tubal abnormalities	Ectopic (tubal) pregnancy, endometriosis
Etiology of salpingitis	Fundamental cause	Almost always infectious
Sexually transmitted organisms	Classic PID pathogens	Neisseria gonorrhoeae, Chlamydia trachomatis
Nongonococcal organisms	Important contributors	Chlamydia, Mycoplasma hominis, coliforms
Postpartum infections	Typical organisms	Streptococci, Staphylococci
Gonococcal infection	Morphologic pattern	Similar to male genital tract gonococcal infection
Coliform / streptococcal / staphylococcal infection	Tissue behavior	Penetrate tubal wall
	Systemic consequence	Can cause blood-borne (hematogenous) spread to distant sites
Tuberculous salpingitis	Frequency	Rare
	Association	Almost always with tuberculous endometritis
Clinical features (all types)	Systemic symptoms	Fever
	Pain	Lower abdominal pain, pelvic pain
	Pelvic findings	Pelvic mass
Cause of pelvic mass	Pathophysiology	Distension of fallopian tubes by exudate or inflammatory debris
Local spread of inflammation	Adhesions	Inflamed tube adheres to ovary and adjacent ligamentous tissues
Severe complication	Tubo-ovarian abscess	Adhesion between tube + ovary → tubo-ovarian abscess
Healing phase	Residual damage	Adhesions persist between ovary and tubes
Tubal plicae involvement	Critical sequela	Adhesions of tubal plicae
Major reproductive risk	Ectopic pregnancy	Plicae adhesions → ↑ risk of tubal ectopic pregnancy
Luminal damage	Fertility impact	Obstruction or damage of tubal lumen → permanent sterility
Fallopian tube carcinoma	Old concept	Primary adenocarcinoma considered rare
Current understanding	New paradigm	Many high-grade serous “ovarian” carcinomas originate in fallopian tube
Precursor lesion	Name	Serous Tubal Intraepithelial Carcinoma (STIC)
STIC location	Anatomy	Fimbriated end of fallopian tube
STIC genetics	Molecular feature	TP53 mutation in >90% of cases
Genetic risk population	High-risk groups	Frequently found in BRCA1 / BRCA2 mutation carriers
Prophylactic surgery finding	Evidence	STIC found in prophylactically removed tubes
Sporadic cancer link	Broader implication	Also found (less commonly) in women without known genetic risk
Tumor origin concept	Key idea	Many sporadic “ovarian” serous carcinomas originate in tube
Anatomical explanation for spread	Fimbrial anatomy	Fimbriated end is intimately associated with ovary
	Peritoneal access	Tube has direct access to peritoneal cavity
Pattern of spread at presentation	Sites involved	Ovary, omentum, peritoneal cavity
Clinical implication	Disease stage	Often advanced disease at presentation

Ultra-High-Yield Exam Locks

Most common tubal disorder → salpingitis (PID)
Postpartum salpingitis → streptococci + staphylococci
Plicae adhesions → ectopic pregnancy
Luminal damage → permanent sterility
High-grade serous “ovarian” cancer → often tubal origin
STIC + TP53 + BRCA = exam gold

🥚 OVARIES

TUMORS OF THE OVARY — COMPLETE MASTER TABLE (ZERO OMISSION)

I. OVERVIEW & ORIGIN

Feature	Details
Annual burden (US, 2016)	>20,000 cases; >14,000 deaths
Rank in female cancer mortality	5th leading cause
Cell of origin (3 types)	1️⃣ Surface (coelomic) epithelium 2️⃣ Germ cells 3️⃣ Sex cord–stromal cells
Most common origin	Surface epithelial tumors
% of ovarian tumors	Epithelial ≈ majority
% of ovarian cancers	≈ 90% epithelial
Germ cell + sex cord tumors	20–30% of tumors, <10% malignant

II. SURFACE EPITHELIAL TUMORS — GENERAL FEATURES

Feature	Details
True origin (modern view)	Many arise from fimbrial end of fallopian tube
Cortical cyst epithelium	From displaced ovarian surface epithelium or tubal epithelium
Pathogenesis	Metaplasia → neoplasia
Benign forms	Cystadenoma ± cystadenofibroma
Malignant forms	Cystadenocarcinoma (cystic) or carcinoma (solid)
Borderline tumors	Intermediate behavior; recur; may progress
Risk factors	Nulliparity, family history
Protective factor	Prolonged oral contraceptive use
Familial cases	5–10%
Key genes (familial)	BRCA1, BRCA2
Lifetime ovarian cancer risk	BRCA1 ≈ 30%; BRCA2 lower
Sporadic tumors	BRCA mutations in only 8–10%

III. SERIOUSLY HIGH-YIELD: SURFACE EPITHELIAL SUBTYPES

A. SEROUS TUMORS

Feature	Details
Frequency	Most common ovarian tumor overall
Benign	~60%
Borderline	~15%
Malignant	~25%
Benign age group	30–40 years
Malignant age group	45–65 years

Low-Grade vs High-Grade Serous Carcinoma

Feature	Low-Grade	High-Grade
Origin	Benign / borderline lesions	STIC in fimbrial fallopian tube
Progression	Slow, stepwise	Rapid
Key mutations	KRAS, other signaling genes	TP53 (>95%), NF1, RB
BRCA association	Uncommon	Common in familial cases
Aggressiveness	Lower	Very high

Morphology — Serous Tumors

Aspect	Features
Gross size	Large, spherical/ovoid
Diameter	Up to 30–40 cm
Bilaterality (benign)	~25%
Benign surface	Smooth, glistening
Malignant surface	Nodular irregularities (serosal invasion)
Cut section	Uni- or multiloculated cysts
Contents	Clear serous fluid
Papillae	Present; more prominent in malignancy

Histology-Serous tumors

Tumor Type	Microscopic Features
Benign	Single layer ciliated columnar cells
Psammoma bodies	Common
Borderline	Mild atypia, no stromal invasion, may seed peritoneum
High-grade carcinoma	Marked atypia, complex papillae, stromal invasion

Spread & Prognosis

Feature	Details
Spread	Peritoneal cavity, para-aortic LN
Distant mets	Rare
Stage I survival	~90%
Advanced stage survival	<40%
Borderline tumors	≈ 100% survival
BRCA tumors	Better prognosis

B. MUCINOUS TUMORS

Feature	Details
Epithelium	Mucin-secreting
Benign	~80%
Borderline	~10%
Malignant	~10%
KRAS mutation	~50%
Prognosis	Better than serous
Major determinant	Stage, not histology

Morphology-Mucinous tumors

Feature	Details
Gross	Very large, multicystic
Contents	Mucin
Bilaterality	Uncommon
Malignancy clues	Solid areas, serosal penetration
Histology	Stratification, atypia, stromal invasion

Special Associations-Mucinous tumors

Condition	Notes
Krukenberg tumor	GI metastases → bilateral ovaries
Pseudomyxoma peritonei	Usually appendiceal origin
Rupture	Peritoneal seeding (often regresses)

C. ENDOMETRIOID TUMORS

Feature	Details
Architecture	Tubular glands (endometrial-like)
Association	Endometriosis
Behavior	Usually malignant
Bilaterality	~30%
Concomitant endometrial CA	15–30%
Key genes	PTEN, PI3K-AKT pathway

D. BRENNER TUMOR

Feature	Details
Frequency	Rare
Laterality	Usually unilateral
Gross	Solid, gray-white, encapsulated
Size	Few cm → 20 cm
Histology	Transitional-type epithelium
Possible origin	Surface epithelium or trapped urogenital epithelium
Behavior	Mostly benign; borderline/malignant rare

IV. GERM CELL TUMORS

TERATOMAS (15–20% of ovarian tumors)

A. BENIGN (MATURE) CYSTIC TERATOMA

Feature	Details
Age	Young women
Layers present	Ectoderm, mesoderm, endoderm
Common name	Dermoid cyst
Laterality	90% unilateral (right > left)
Size	Usually <10 cm
Gross	Sebum, hair, teeth
Complications	Torsion (10–15%), infertility
Paraneoplastic	Limbic encephalitis
Malignant transformation	~1% (usually SCC)

B. IMMATURE (MALIGNANT) TERATOMA

Feature	Details
Mean age	18 years
Gross	Bulky, solid, necrotic
Histology	Immature cartilage, bone, muscle, nerve
Prognosis	Grade + stage dependent

C. SPECIALIZED TERATOMAS

Type	Key Feature
Struma ovarii	Thyroid tissue → hyperthyroidism
Ovarian carcinoid	Rare carcinoid syndrome

V. SALIENT FEATURES — OTHER OVARIAN NEOPLASMS

GERM CELL & SEX CORD–STROMAL TUMORS

Tumor	Age	Laterality	Key Morphology	Behavior
Dysgerminoma-Germ cell	2nd–3rd decade	Unilateral	Clear cells, lymphocytes	Malignant, radiosensitive
Choriocarcinoma-Germ cell	Young	Unilateral	Cytotrophoblast + syncytiotrophoblast	Early widespread mets
Granulosa-theca	Postmenopausal	Unilateral	Call-Exner bodies	Estrogenic
Thecoma-fibroma	Any	Unilateral	Yellow lipid cells	Meigs syndrome
Sertoli-Leydig	Any	Unilateral	Testis-like cords	Masculinizing
Metastases	Older	Bilateral	Signet-ring cells(krukenberg)	GI, breast, lung

VI. CLINICAL FEATURES & MARKERS

Feature	Details
Early symptoms	Usually absent
Common presentation	Large mass, pressure symptoms
Ascites	Malignant serous tumors
Torsion	Dermoid cysts
Functional tumors	Endocrinopathies
Screening	Poor
CA-125	↑ in 75–90% epithelial tumors
Limitation	Poor early detection
Best use	Monitoring therapy response

Type I vs Type II Ovarian Tumors — Exam Table

Exam feature	Type I (Slow / Stepwise / “Low-grade pathway”)	Type II (Fast / Aggressive / “High-grade pathway”)
Big idea	Indolent, develops step-by-step from a recognizable precursor	Highly aggressive, develops rapidly, often de novo
Typical stage at diagnosis	Often earlier stage (I–II)	Often advanced stage (III–IV)
Growth & spread	Slower growth; more localized early	Rapid growth; early peritoneal spread/ascites
Genomic pattern	Relative genetic stability	Marked genomic instability
Prototype tumor	Low-grade serous carcinoma	High-grade serous carcinoma (HGSC) (the big one)
Common histologies included	Low-grade serous, mucinous, endometrioid (low-grade), clear cell (often grouped here), malignant Brenner (rare)	HG serous, undifferentiated carcinoma, carcinosarcoma (MMMT) (± some high-grade endometrioid in some schemes)
Precursor lesion	Often arises from benign/borderline tumors (e.g., serous borderline → low-grade serous)	Often arises from STIC (Serous Tubal Intraepithelial Carcinoma) in fimbrial tube
Site of origin (concept)	More “ovary/cortical inclusion cyst” pathway (traditional teaching)	More “fallopian tube fimbria” origin (STIC → HGSC)
Key driver gene theme	Oncogene-pathway mutations (signal transduction)	TP53-centered pathway ± DNA repair failure
Typical mutations (high-yield)	KRAS, BRAF, ERBB2(HER2) (esp mucinous), PTEN, PIK3CA, ARID1A, CTNNB1 (β-catenin) (esp endometrioid/clear cell groups)	TP53 (vast majority of HGSC), BRCA1/BRCA2 (germline or somatic), other homologous recombination genes
p53 IHC clue	Often wild-type pattern (unless unusual)	Often abnormal p53 pattern (mutation pattern)
Borderline tumor link	Strong link (esp serous borderline → low-grade serous)	No borderline stage typically
Typical patient profile	Slightly younger than Type II (varies by subtype)	Often older, postmenopausal tendency
Chemosensitivity	Often less chemo-responsive (because slower-growing); surgery important	Often more chemo-responsive initially (platinum-based) but high relapse risk
Prognosis (overall)	Generally better (because earlier stage + indolent)	Generally worse (advanced stage + aggressive biology)
One-line memory hook	“Type I = I for Indolent, Increments (stepwise)”	“Type II = Too aggressive, TP53, Tubal (STIC)”

Ultra-fast recall (1-liners)

Type I: Borderline/benign precursor → stepwise → KRAS/BRAF/PTEN/PIK3CA/ARID1A
Type II: STIC (fimbria) → HGSC → TP53 ± BRCA → widespread peritoneal disease

Note-

1) Follicular & Luteal Cysts (Functional cysts = near-normal physiology)

Why they happen

From unruptured Graafian follicle OR follicle ruptures then immediately seals.

Where / how they look

Often multiple, just under ovarian serosa (subserosal/subjacent).
Usually small: 1–1.5 cm, filled with clear serous fluid.

When they matter clinically

Can enlarge to 4–5 cm → palpable mass + pelvic pain.
Lining: early granulosa cells (follicular cyst) or luteal cells (luteal cyst).
As fluid ↑ → pressure → atrophy of lining cells.

Complication

Rupture → intraperitoneal bleeding → peritoneal irritation → acute abdomen picture.

2) Polycystic Ovarian Syndrome (PCOS / Stein-Leventhal)

Core syndrome (definition bundle)

Hyperandrogenism + menstrual abnormalities + polycystic ovaries + chronic anovulation + ↓ fertility.

Typical presentation

Often noticed after menarche (teens/young adults):

Oligomenorrhea, hirsutism, infertility, ± obesity.

Gross ovary

Ovaries about 2× normal size, gray-white, smooth outer cortex
Subcortical cysts: 0.5–1.5 cm.

Histology (high-yield “why it looks like that”)

Thickened fibrotic capsule
Innumerable cystic follicles lined by granulosa cells
Hyperplastic luteinized theca interna
Absent corpora lutea → fits chronic anovulation.

3) Ovarian Tumors: big framework

Why ovarian tumors are so varied

Can arise from 3 normal ovarian cell sources:

Surface (coelomic) epithelium (incl. cortical epithelial cysts / tubal-type epithelium)
Germ cells (totipotent)
Sex cord–stromal cells

Epithelial tumors dominate

Great majority of ovarian tumors.
Malignant epithelial tumors account for ~90% of ovarian cancers.
Germ cell + sex cord–stromal tumors: 20–30% of ovarian tumors, but <10% of malignant ovarian tumors.

4) Surface epithelial tumors: origin + categories

Modern concept of origin

Many “ovarian” epithelial cancers actually arise from fimbrial end of fallopian tube (not true ovarian surface).
Ovarian cortical epithelial cysts may come from displaced ovarian surface epithelium or tubal epithelium → metaplasia / neoplastic transformation.

Category ladder

Benign: usually cystic = cystadenoma (± stromal component = cystadenofibroma)
Malignant: cystadenocarcinoma (cystic) or carcinoma (solid)
Borderline tumors: intermediate; mostly benign behavior but can recur, some progress to carcinoma.

5) Ovarian cancer risk factors (must-remember exam set)

Higher risk

Nulliparity / low parity, family history, germline tumor suppressor mutations.
Higher incidence in unmarried and married with low parity.

Protective

Prolonged oral contraceptive use ↓ risk.

Familial / BRCA

5–10% ovarian cancers are familial, mostly BRCA1/BRCA2.
Lifetime ovarian cancer risk:

BRCA1 ~30%
BRCA2 lower than BRCA1

In sporadic ovarian cancers: BRCA1/2 mutations only ~8–10% → many arise via other mechanisms.

6) Serous Tumors (most common epithelial; biggest malignant fraction)

Frequency split

60% benign, 15% borderline, 25% malignant.

Age

Benign: 30–40 yrs
Malignant: 45–65 yrs

Two carcinoma pathways

Low-grade serous carcinoma

Slow, stepwise progression from benign/borderline lesions
Often KRAS (signaling pathway genes)

High-grade serous carcinoma

Rapid development
Often from fimbrial tube via serous tubal intraepithelial carcinoma (STIC)
TP53 mutation >95% (virtually universal)
Other common: NF1, RB; BRCA1/2 in familial cases

Morphology

Often large, cystic, 30–40 cm, spherical/ovoid.
Bilateral: ~25% of benign serous tumors.
Benign: smooth, glistening surface.
Malignant: nodular irregularities where tumor invades serosa.
Cut section: unilocular or multiloculated (septa), clear serous fluid, papillary projections (more prominent in malignant).
Histology:

Benign: single layer columnar, often ciliated
Psammoma bodies common (calcified laminated bodies) at papilla tips
High-grade malignant: marked atypia, complex multilayered papillae, stromal invasion
Borderline: less atypia, no stromal invasion, may seed peritoneum but usually noninvasive implants

Spread

Malignant serous tumors: spread widely in peritoneal cavity + regional nodes (periaortic).
Distant blood spread less common.

Prognosis

High-grade: generally poor, strongly stage-dependent.
5-yr survival:

Confined to one ovary ~90%
Higher stages: <40% (depends on stage)

Borderline tumors: ~100% survival
BRCA1/2-mutated tumors often have better prognosis than non-mutated.

7) Mucinous Tumors

Key differences vs serous

Lining epithelium is mucin-secreting
Much less likely malignant

Frequency

80% benign, 10% borderline, 10% malignant

Morphology

Usually larger, often multicystic; contents are mucinous.
Serosal penetration + solid areas → suggest malignancy.
Malignancy histology: stratification/piling up, atypia, stromal invasion.

Bilateral?

Much less likely bilateral than serous.
Helps differentiate from metastatic GI mucinous adenocarcinoma (often bilateral) → classic example: Krukenberg tumor.

Peritoneal issues

Rupture may seed peritoneum but often regress.
Persistent mucin implants with lots of mucin = pseudomyxoma peritonei (most often from GI tract, especially appendix).

Genetics

KRAS mutations ~50% in ovarian mucinous carcinoma (not helpful to separate from GI metastases—GI primaries also commonly KRAS).

Outcome

Somewhat better than serous, but stage > histologic type for prognosis.

8) Endometrioid Tumors

Can be solid or cystic, sometimes linked with endometriosis.
Microscopy: tubular glands like endometrium lining cystic spaces.
Usually malignant (though benign/borderline exist).
Bilateral ~30%.
15–30% have concomitant endometrial carcinoma.
Genetics: often PTEN mutations + other changes activating PI3K-AKT.

9) Brenner Tumor

Uncommon, solid, usually unilateral.
Lots of stroma with nests of transitional-type epithelium (urinary-tract like).
Sometimes nests become cystic and lined by columnar mucin-secreting cells.
Encapsulated, gray-white, size from few cm to 20 cm.
Possible origin: surface epithelium or trapped urogenital epithelium in germinal ridge.
Mostly benign, but borderline/malignant described.

10) Teratomas (germ cell; high-yield clinical)

15–20% of ovarian tumors.
Often occur in first 2 decades; younger age = higher malignancy risk, BUT:

>90% are benign mature cystic teratomas (dermoid cysts)
Immature malignant teratoma is rare

A) Mature cystic teratoma (dermoid)

Mature tissues from ectoderm + endoderm + mesoderm.
Often: cyst lined by epidermis with adnexal appendages.
Found in young women; may be incidental (imaging shows calcification/toothlike structures).
~90% unilateral, right > left.
Usually <10 cm.
Cut section: sebaceous material + hair; may have teeth, sometimes bone/cartilage, bronchial/GI epithelium, etc.
Clinical issues:

Can cause infertility
Torsion 10–15% → acute emergency
Rare paraneoplastic: limbic encephalitis (esp. if mature neural tissue) → may remit after resection
Malignant transformation ~1%, usually squamous cell carcinoma

B) Immature malignant teratoma

Mean age ~18 yrs.
Bulky, solid, often necrosis; may have cystic foci.
Microscopy: immature elements / minimally differentiated cartilage, bone, muscle, nerve, etc.
Prognosis depends on grade + stage.

C) Specialized teratomas

Struma ovarii: thyroid tissue only → may cause hyperthyroidism.
Ovarian carcinoid: rarely causes carcinoid syndrome.

11) Clinical features + screening reality

Why they’re dangerous: many are silent until advanced.
Symptoms when large:

Pressure symptoms: pain, GI complaints, urinary frequency
↑ abdominal girth with big epithelial tumors

Torsion: more with smaller masses like dermoid cyst → severe pain mimics acute abdomen.
Ascites: often with malignant serous tumor peritoneal seeding.
Functioning tumors: present via endocrinopathies.
Treatment: still not ideal, only modest survival gains since mid-1970s.
CA-125

Elevated in 75–90% epithelial ovarian cancers.
But up to 50% of cancers confined to ovary have normal/undetectable CA-125.
Also elevated in many benign conditions + non-ovarian cancers.
Best use: monitoring treatment response.

12) Other important ovarian tumors (table facts that examiners pick)

Dysgerminoma

2nd–3rd decade; unilateral 80–90%
Testicular seminoma counterpart; malignant but only ~1/3 metastasize
Radiosensitive, ~80% cure

Choriocarcinoma (ovary)

Early decades; metastasizes early and widely
Primary may regress → only metastases found
Resistant to chemotherapy

Granulosa-theca cell tumor

Often postmenopausal; can be any age; unilateral
Can produce lots of estrogen
Granulosa part malignant 5–25%

Thecoma-fibroma

Often hormonally inactive; rarely malignant
~40% with Meigs syndrome (ascites + hydrothorax)

Sertoli-Leydig cell tumor

Any age; many cause masculinization/defeminization; rarely malignant

Metastases to ovary

Older age; mostly bilateral
Primaries: GI tract (Krukenberg), breast, lung
Can show signet ring mucin-secreting cells

Diseases of pregnancy

Gestational Trophoblastic Disease (GTD) + Preeclampsia/Eclampsia — Complete Integrated Table

A. Gestational Trophoblastic Disease (GTD)

Domain	Complete Hydatidiform Mole	Partial Hydatidiform Mole	Invasive Mole	Choriocarcinoma	Placental Site Trophoblastic Tumor (PSTT)
WHO Category	Molar	Molar	Molar (locally invasive)	Non-molar	Non-molar
Core Pathogenesis	Excess paternal genome only → unchecked trophoblast	Excess paternal genome with maternal contribution	Complete mole with deep myometrial invasion	Malignant trophoblast with early vascular invasion	Neoplasm of intermediate trophoblast
Fertilization / Genetics	Diploid 46,XX (most) or 46,XY; all paternal (empty egg + 2 sperm or diploid sperm)	Triploid 69,XXY (most); normal egg + 2 sperm	Same as complete mole	Variable; gestational or germ-cell origin	Diploid, often XX
Embryo / Fetal Parts	Absent	May be present	Absent	Absent	Absent
Chorionic Villi	All villi abnormal (hydropic)	Mixed normal + abnormal villi	Present and hydropic	Absent	Absent
Trophoblast Proliferation	Diffuse (cyto + syncytio)	Focal, mild	Marked	Marked, anaplastic	Intermediate trophoblast
Gross Appearance	Grapelike, cystic villi filling uterus	Similar but less diffuse	Invasive, destructive	Hemorrhagic, necrotic masses	Often nodular at placental site
β-hCG Level	Very high	Elevated (less than complete)	Persistently elevated	Extremely high	Low–mild elevation
Other Hormone	—	—	—	—	hPL ↑
Uterine Size	Enlarged, classically “large for dates”	Mild enlargement	Enlarged, invasive	Not markedly enlarged	Variable
Clinical Clues	No FHS, high hCG	Possible fetal tissue	Persistent bleeding, invasion	Brown/bloody discharge, high hCG	Months after pregnancy, low hCG
Metastasis	No	No	No true metastasis (embolized villi may regress)	Early hematogenous spread	Occurs late
Common Spread Sites	—	—	—	Lung (50%), vagina (30–40%), brain, liver, kidney	Beyond uterus = poor prognosis
Chemo Sensitivity	High (if needed)	Rarely needed	Very good	Excellent (≈100% cure)	Poor
Prognosis	Excellent	Excellent	Excellent with chemo	Excellent (placental type)	Good if uterine-confined
Progression Risk	~10% invasive; 2–3% choriocarcinoma	Very low	—	Aggressive but curable	Poor once extra-uterine

B. Epidemiology & Risk Pattern (Moles)

Feature	Details
Incidence (Complete Mole)	1–1.5 / 2000 pregnancies (West)
Geographic Pattern	Higher in Asian countries
Age Risk	<20 yrs and >40 yrs
Recurrence Risk	Increased after prior mole
Detection Trend	Earlier now due to routine ultrasound

C. Monitoring & Management Logic (All GTD)

Principle	Clinical Meaning
Universal Marker	β-hCG
Diagnosis	Abnormally high hCG
Follow-up	Serial hCG until undetectable
Outcome Prediction	hCG trend > histologic grading
Persistent Disease	Rising/plateau hCG → chemo
Cure Rates	Very high with correct monitoring

D. Preeclampsia / Eclampsia — Mechanism-First Table

1. Definitions

Term	Definition
Preeclampsia	HTN + proteinuria ± edema after mid-pregnancy
Eclampsia	Preeclampsia + seizures
Incidence	5–10% of pregnancies
High-Risk Groups	First pregnancy, age >35
Old Term	“Toxemia of pregnancy” (incorrect)

2. Core Pathogenesis (Single Root Cause)

Step	Pathologic Event	Consequence
1	Inadequate spiral artery remodeling	Narrow, high-resistance vessels
2	Reduced uteroplacental flow	Placental hypoxia
3	Placental dysfunction	Release of anti-angiogenic factors
4	↑ sFlt-1, sEng; ↓ VEGF	Endothelial dysfunction
5	Systemic vasculopathy	Multisystem disease

3. Major Clinical Consequences

System	Mechanism	Outcome
Blood Pressure	↓ prostacyclin/PGE₂, ↑ TXA₂	Hypertension
Coagulation	Endothelial damage + tissue factor	Hypercoagulability
Kidney	Endothelial injury	Proteinuria, renal failure
Liver	Microangiopathy	Elevated enzymes
Placenta	Hypoperfusion	Infarction, abruption

4. HELLP Syndrome

Component	Mechanism
Hemolysis	Microangiopathic
Elevated Liver Enzymes	Hepatic endothelial injury
Low Platelets	Consumption ± DIC
Frequency	~10% of severe preeclampsia

5. Morphology

Placenta

Finding	Significance
Multiple infarcts	Chronic hypoperfusion
Retroplacental hemorrhage	Severe disease
Premature villous maturation	Placental stress
Syncytial knots ↑	Hypoxia marker

Decidual Vessels

Lesion	Meaning
Fibrinoid necrosis	Severe vascular injury
Acute atherosis	Lipid-laden macrophages

6. Clinical Course Rule (Exam Gold)

Rule	Implication
Early treatment	Prevents organ damage
Delivery	Disease resolves
Delay	Risk of eclampsia, HELLP

One-Line Exam Anchors

GTD management is guided by β-hCG trend, not histology.
Choriocarcinoma: no villi, early blood spread, chemo-curable.
PSTT: low hCG, hPL positive, surgery-dominant management.
Preeclampsia = failed spiral artery remodeling → endothelial dysfunction → multisystem disease.

1) Gestational Trophoblastic Disease (GTD) — core idea

Definition: Abnormal proliferation of fetal trophoblast cells.
Why the umbrella term matters clinically: What predicts response and guides management best is hormone behavior (hCG trend) more than fine pathology subtyping.
Shared biochemical hallmark: All GTD lesions elaborate hCG, detectable in blood/urine at levels higher than normal pregnancy.

Diagnosis: unusually high hCG helps suspect GTD.
Monitoring: serial β-hCG is used to track treatment efficacy and detect persistent disease/relapse.

2) WHO classification — the map

A) Molar lesions

Complete hydatidiform mole
Partial hydatidiform mole
Invasive hydatidiform mole (locally invasive form, typically from complete mole)

B) Nonmolar lesions

Choriocarcinoma
Other uncommon trophoblast-derived malignancies (includes placental site trophoblastic tumor discussed later)

3) Hydatidiform mole (general picture)

Gross “look”: Uterus filled with swollen, cystically dilated chorionic villi → looks like grapelike clusters.
Surface lining: swollen villi are covered by chorionic epithelium showing variable atypia (from normal → highly atypical).

4) Complete vs Partial mole — logic from fertilization → genetics → phenotype

A) Shared mechanism

Both result from abnormal fertilization with excess paternal genetic material (paternal genome predominance drives trophoblastic proliferation).

B) Complete hydatidiform mole

Genetics / formation

Diploid: usually 46,XX, less commonly 46,XY.
All genetic content is paternal:

A typical mechanism is an “empty” egg + two sperm (or one diploid sperm) → diploid conceptus with only paternal chromosomes.

Embryo/fetus

Not compatible with embryogenesis
Rarely contains fetal parts

Villi

All chorionic villi are abnormal

C) Partial hydatidiform mole

Genetics / formation

Triploid: almost always 69,XXY (example given).
Mechanism: a normal egg fertilized by two sperm (or a diploid sperm) → triploid with preponderance of paternal genes.

Embryo/fetus

Compatible with early embryo formation
May contain fetal parts (and often does)

Villi

Some normal chorionic villi remain (mixture of normal + abnormal)

5) Epidemiology + risk pattern + how we find it now

Incidence (complete mole): about 1 to 1.5 per 2000 pregnancies in the US/Western countries.
Higher incidence in Asian countries (reason stated as unknown).
Age risk: more common <20 years and >40 years.
Recurrence risk: history of molar disease increases risk in subsequent pregnancies.
Detection shift: Previously discovered around 12–14 weeks when uterus was “too large for dates”; now earlier due to routine ultrasound monitoring.

6) Clinical pattern of complete/partial moles (what you expect at bedside)

hCG elevated in maternal blood
Absent fetal heart sounds (typical)
Follow-up outcomes after evacuation:

80–90% do not recur after thorough curettage.
~10% of complete moles become invasive.
2–3% (max) progress to choriocarcinoma.

7) Morphology (moles) — what pathology shows, and why grading is outdated

Gross (advanced cases)

Uterine cavity expanded by a delicate, friable mass of thin-walled, translucent cystic structures.
Fetal parts

Rare in complete moles
Common in partial moles

Microscopy — complete mole

Hydropic swelling of poorly vascularized chorionic villi
Loose, myxomatous, edematous stroma
Trophoblast proliferation: both

Cytotrophoblasts
Syncytiotrophoblasts

Microscopy — partial mole

Villous edema involves only a subset of villi
Trophoblast proliferation: focal and slight
Fetal cells often present

can be as minimal as fetal red cells in villi
rarely can include a fully formed fetus

Key clinical update

Histologic grading to predict outcome has been replaced by serial hCG monitoring.

8) Invasive mole — “deep invasion without true metastasis”

Typically a complete mole that becomes locally invasive.
Key retained feature: still has hydropic villi.
Behavior: villi penetrate deeply into uterine wall → can cause

uterine rupture
life-threatening hemorrhage

Microscopy: atypia with proliferation of both trophoblastic components:

trophoblastic + syncytiotrophoblast components (as described)

Metastases do not occur (important contrast with choriocarcinoma)

Hydropic villi can embolize to distant organs (lungs/brain), but

they do not behave like true metastases
may regress spontaneously

Treatment logic

Because invasion is deeper, complete curettage is difficult
If β-hCG remains elevated, further therapy is needed
Chemotherapy usually cures most cases

9) Gestational choriocarcinoma — “no villi + early vascular spread + very chemo-sensitive”

Origin

Very aggressive malignant tumor
Arises from:

gestational chorionic epithelium (common)
less commonly from totipotential gonadal germ cells (ovary/testis)

Epidemiology

Rare in Western hemisphere: about 1 per 30,000 pregnancies in the US
Much more common in Asian and African countries: up to 1 in 2000 pregnancies

Antecedent pregnancy events (proportions)

~50% arise from complete hydatidiform moles
~25% arise after an abortion
remainder follow an apparently normal pregnancy

Presentation (clinical logic)

Bloody, brownish discharge
Rising β-hCG in blood/urine
No marked uterine enlargement (unlike molar pregnancy)
β-hCG titers are generally much higher than with a mole

Morphology

Gross: hemorrhagic, necrotic uterine masses

necrosis can be so extensive that little viable tumor remains
primary may “self-destruct”; metastases may reveal diagnosis

Invasion pattern: early myometrial and vascular invasion
Microscopy: no chorionic villi

composed of anaplastic:

cytotrophoblasts
syncytiotrophoblasts

Spread pattern (vascular >> lymphatic)

By discovery, widespread vascular spread usually present
Common sites and frequencies given:

Lungs ~50%
Vagina ~30–40%
also brain, liver, kidneys

Lymphatic invasion uncommon

Treatment / prognosis logic

Despite aggression, placental choriocarcinoma is highly chemo-sensitive

Nearly 100% cured, even with distant metastases (e.g., lungs)

Gonadal choriocarcinoma (ovary/testis) responds relatively poorly
Proposed reason for placental tumors doing better:

presence of paternal antigens → maternal immune response may help clear tumor alongside chemotherapy

10) Placental Site Trophoblastic Tumor (PSTT) — “intermediate trophoblast + low hCG + less chemo-sensitive”

Cell of origin: intermediate trophoblast at placental site (overlaps features of cyto- and syncytiotrophoblasts).
Genetics: diploid, often XX.
Timing: typically arises a few months after pregnancy.
Hormone pattern

intermediate trophoblasts do not produce large hCG → hCG only slightly elevated
more typical product: human placental lactogen (hPL)

Clinical course: often indolent

favorable if confined to endomyometrium

Chemo sensitivity: not as sensitive as other trophoblastic tumors

prognosis becomes poor once spread occurs beyond uterus

🟦 Gestational Trophoblastic Disease — Single Comprehensive Comparison Table

Feature	Complete Mole	Partial Mole	Invasive Mole	Gestational Choriocarcinoma	Placental Site Trophoblastic Tumor (PSTT)
Basic nature	Benign trophoblastic proliferation	Benign but abnormal trophoblastic proliferation	Locally invasive form of mole	Highly malignant trophoblastic tumor	Rare trophoblastic tumor
Common origin	Fertilization of empty ovum	Triploid conception	Usually evolves from complete mole	Usually after mole, abortion, or normal pregnancy	Arises from intermediate trophoblast
Genetics	Androgenetic diploid (usually XX)	Triploid (e.g. 69XXY)	Same as complete mole	Gestational (placental) or rarely gonadal	Diploid, often XX
Gross appearance	Uterine cavity expanded by delicate, friable, thin-walled translucent cystic vesicles	Similar but less diffuse	Often destructive, invasive mass	Hemorrhagic, necrotic uterine mass	Nodular infiltrative lesion at placental site
Fetal parts	Rare / absent	Common	Absent	Absent	Absent
Chorionic villi	Present	Present (subset only)	Present (hydropic)	Absent	Absent
Villous edema	Diffuse hydropic swelling	Focal villous edema	Hydropic villi invade myometrium	—	—
Villous vascularity	Poorly vascularized	Partly vascularized	Poor	—	—
Stroma	Loose, myxomatous, edematous	Mild–moderate edema	Similar to complete mole	—	—
Trophoblast proliferation	Diffuse, circumferential	Focal, slight	Marked with atypia	Anaplastic, aggressive	Sheets of intermediate trophoblast
Trophoblast types	Cytotrophoblast + Syncytiotrophoblast	Same (mild)	Cytotrophoblast + Syncytiotrophoblast	Cytotrophoblast + Syncytiotrophoblast	Intermediate trophoblast
Depth of invasion	Confined to endometrium	Confined	Deep myometrial invasion	Early myometrial + vascular invasion	Endomyometrium initially
Metastasis	No	No	No true metastases	Early, widespread vascular spread	Late, uncommon
Embolization	No	No	Hydropic villi may embolize (lung/brain) but regress	True metastases	Rare
Common metastatic sites	—	—	—	Lung (~50%), vagina (30–40%), brain, liver, kidney	—
Uterine size	Enlarged	Mildly enlarged	Variable	Not markedly enlarged	Often normal
β-hCG levels	Very high	Mild–moderate rise	Persistently elevated	Extremely high	Low or mildly elevated
Other hormones	—	—	—	—	hPL increased
Clinical presentation	Vaginal bleeding, enlarged uterus	Vaginal bleeding	Hemorrhage, uterine rupture	Bloody brown discharge, high hCG	Abnormal bleeding months after pregnancy
Histologic grading	Outdated	Outdated	Not used	Not applicable	Not useful
Current monitoring	Serial β-hCG	Serial β-hCG	Serial β-hCG	Serial β-hCG	hCG unreliable
Chemo sensitivity	Not needed	Not needed	Highly sensitive	Extremely chemo-sensitive	Poor chemo response
Primary treatment	Suction curettage	Suction curettage	Chemo if hCG persists	Chemotherapy	Surgery (hysterectomy)
Prognosis	Excellent	Excellent	Excellent with chemo	~100% cure (gestational)	Good if confined, poor if spread
Key exam discriminator	No fetus + diffuse villi	Fetal tissue present	Villi + invasion	No villi + early vascular spread	Low hCG, hPL positive

🧠 Ultra-high-yield exam locks

Villi present → NOT choriocarcinoma
Invasion + villi → invasive mole
No villi + very high hCG + lung mets → choriocarcinoma
Low hCG + hPL + poor chemo response → PSTT
Histologic grading = obsolete → serial hCG is king

If you want, I can:

🔁 convert this into XMind-paste format
🧪 generate spotter-style MCQs
🔍 add immunohistochemistry row (hCG, hPL, Ki-67)

11) Preeclampsia / Eclampsia — mechanism-first, then consequences, then morphology

A) Definitions

Preeclampsia: hypertension + proteinuria + edema developing in 3rd trimester
Occurs in 5–10% of pregnancies
Higher risk emphasized in:

first pregnancies
women older than 35

Eclampsia: preeclampsia + seizures
“Toxemia of pregnancy” is an old term and a misnomer (no toxin identified)
Early recognition/treatment has made fatal eclampsia rare

B) Central pathogenesis (one core defect → many downstream problems)

Core defect: insufficient maternal blood flow to placenta due to inadequate spiral artery remodeling

Normal pregnancy:

trophoblast invasion replaces musculoelastic walls of spiral arteries
arteries dilate into wide vascular sinusoids

Preeclampsia/eclampsia:

remodeling is impaired
musculoelastic walls are retained
channels remain narrow

→ leads to decreased uteroplacental blood flow → placental hypoxia/dysfunction

Angiogenic imbalance (circulating factors)

Increased anti-angiogenic factors: sFlt1 and sEng
Reduced pro-angiogenic factors: e.g., VEGF

→ hypothesized to cause:

endothelial dysfunction
vascular hyperreactivity
end-organ microangiopathy

C) Major consequences (with the logic of “endothelium damaged + hypoperfusion”)

Placental infarction from chronic hypoperfusion
Hypertension mechanism described:

decreased endothelial production of vasodilators prostacyclin and prostaglandin E2
increased production of vasoconstrictor thromboxane A2

Hypercoagulability

driven by endothelial dysfunction
plus release of tissue factor from placenta

End-organ failure

especially kidney and liver
in full-blown eclampsia

D) HELLP syndrome (subset of severe cases)

Occurs in about 10% of patients with severe preeclampsia
Components:

H: elevated liver enzymes
EL: microangiopathic hemolytic anemia
LP: thrombocytopenia due to platelet consumption
may include full-blown DIC

E) Clinical features timeline

Presents insidiously around 24–25 weeks with:

edema
proteinuria
rising blood pressure

If progresses to eclampsia:

renal function impaired
BP rises further
convulsions may occur

Key clinical rule:

prompt therapy early can abort organ changes
abnormalities resolve promptly after delivery / cesarean section

F) Morphology (variable; correlates somewhat with severity)

Placenta

Infarcts

can occur in normal pregnancy, but are much more numerous in severe disease

Retroplacental hemorrhages
Premature maturation of villi with:

villous edema
hypovascularity
increased syncytial epithelial knots

Decidual vessels show:

fibrinoid necrosis
focal lipid-laden macrophages (acute atherosis)

19.Female genital system

VULVA

VULVA — COMPLETE CONSOLIDATED TABLE (ZERO-OMISSION)

Exam Lock 🔒 (One-Look Recall)

🔹 Vulvitis

⚙️ Causes

⚠️ Complication

🔹 Non-Neoplastic Epithelial Disorders

Lichen Sclerosus

Lichen Simplex Chronicus

🔹 Tumors of the Vulva

Condylomas (Genital Warts)

Carcinoma of the Vulva

Extramammary Paget Disease (Vulva)

VAGINA

🦠 Vaginitis

⚠️ Malignant Neoplasms

VAGINA — INFLAMMATORY & MALIGNANT CONDITIONS (COMPLETE TABLE)

🔑 Ultra-High-Yield Exam Locks

CERVIX

CERVIX — Inflammation, Neoplasia & Benign Lesions (Complete Table)

Cervical Squamous Neoplasia — Complete Histological Continuum (One Table)

Progression Logic (Exam Gold Line)

Ultra-Short Memory Lock

🩸 Cervicitis

🧬 Neoplasia of the Cervix — Pathogenesis

🧫 Squamous Intraepithelial Lesion (SIL)

🧠 Invasive Carcinoma of the Cervix

🩹 Endocervical Polyp

UTERUS

🧫 Endometritis

💠 Adenomyosis

🌿 Endometriosis

🩸 ABNORMAL UTERINE BLEEDING

🔹 Clinical Patterns

🔹 Major Causes

🔹 Mechanisms of DUB

🌱 ENDOMETRIAL HYPERPLASIA

ENDOMETRIAL HYPERPLASIA — COMPLETE INTEGRATED TABLE (ZERO-OMISSION)

One-line EXAM LOCK 🔒

🧬 ENDOMETRIAL CARCINOMA

Endometrial Carcinoma — Complete Logic-Based Comparison Table (Zero Omission)

One-Line Exam Lock (optional memory anchor)

EXAM-LOCK SUMMARY (ONE-GLANCE)

🌿 ENDOMETRIAL POLYPS

💪 LEIOMYOMA ( = Uterine Fibroid )

⚠️ LEIOMYOSARCOMA

🧬 FALLOPIAN TUBES

Serous Tubal Intraepithelial Carcinoma (STIC)

Endometrial Polyps vs Leiomyoma vs Leiomyosarcoma — Complete Comparison Table

Ultra-High-Yield Exam Locks 🔒

Fallopian Tube Disorders — Complete Integrated Table (Zero Omission)

Ultra-High-Yield Exam Locks

🥚 OVARIES

TUMORS OF THE OVARY — COMPLETE MASTER TABLE (ZERO OMISSION)

I. OVERVIEW & ORIGIN

II. SURFACE EPITHELIAL TUMORS — GENERAL FEATURES

III. SERIOUSLY HIGH-YIELD: SURFACE EPITHELIAL SUBTYPES

A. SEROUS TUMORS

Low-Grade vs High-Grade Serous Carcinoma

Morphology — Serous Tumors

Histology-Serous tumors

Spread & Prognosis

B. MUCINOUS TUMORS

Morphology-Mucinous tumors

Special Associations-Mucinous tumors

C. ENDOMETRIOID TUMORS

D. BRENNER TUMOR

IV. GERM CELL TUMORS

TERATOMAS (15–20% of ovarian tumors)

A. BENIGN (MATURE) CYSTIC TERATOMA

B. IMMATURE (MALIGNANT) TERATOMA

C. SPECIALIZED TERATOMAS

V. SALIENT FEATURES — OTHER OVARIAN NEOPLASMS

GERM CELL & SEX CORD–STROMAL TUMORS

VI. CLINICAL FEATURES & MARKERS

Type I vs Type II Ovarian Tumors — Exam Table

Ultra-fast recall (1-liners)

1) Follicular & Luteal Cysts (Functional cysts = near-normal physiology)

2) Polycystic Ovarian Syndrome (PCOS / Stein-Leventhal)